



Review

# Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach

Piotr Fularski <sup>1</sup>, Witold Czarnik <sup>1</sup>, Bartłomiej Dąbek <sup>1</sup>, Wiktoria Lisińska <sup>1</sup>, Ewa Radzioch <sup>1</sup>, Alicja Witkowska <sup>1</sup>, Ewelina Młynarska <sup>1,\*</sup>, Jacek Rysz <sup>2</sup> and Beata Franczyk <sup>1</sup>

<sup>1</sup> Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland

<sup>2</sup> Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland

\* Correspondence: emmlynska@gmail.com; Tel.: +48-(042)-639-37-50

**Abstract:** Atherosclerotic cardiovascular disease (ASCVD) stands as the leading cause of mortality worldwide. At its core lies a progressive process of atherosclerosis, influenced by multiple factors. Among them, lifestyle-related factors are highlighted, with inadequate diet being one of the foremost, alongside factors such as cigarette smoking, low physical activity, and sleep deprivation. Another substantial group of risk factors comprises comorbidities. Amongst others, conditions such as hypertension, diabetes mellitus (DM), chronic kidney disease (CKD), or familial hypercholesterolemia (FH) are included here. Extremely significant in the context of halting progression is counteracting the mentioned risk factors, including through treatment of the underlying disease. What is more, in recent years, there has been increasing attention paid to perceiving atherosclerosis as an inflammation-related disease. Consequently, efforts are directed towards exploring new anti-inflammatory medications to limit ASCVD progression. Simultaneously, research is underway to identify biomarkers capable of providing insights into the ongoing process of atherosclerotic plaque formation. The aim of this study is to provide a broader perspective on ASCVD, particularly focusing on its characteristics, traditional and novel treatment methods, and biomarkers that can facilitate its early detection.



**Citation:** Fularski, P.; Czarnik, W.; Dąbek, B.; Lisińska, W.; Radzioch, E.; Witkowska, A.; Młynarska, E.; Rysz, J.; Franczyk, B. Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach. *Int. J. Mol. Sci.* **2024**, *25*, 5212. <https://doi.org/10.3390/ijms25105212>

Academic Editor: Nikolaos Kadoglou

Received: 30 March 2024

Revised: 1 May 2024

Accepted: 7 May 2024

Published: 10 May 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).


**Keywords:** atherosclerosis; risk factors; biomarkers; novel treatment

## 1. Introduction

Atherosclerotic cardiovascular disease (ASCVD) continues to stand as the foremost contributor to mortality on a global scale [1]. At the foundation of ASCVD lies atherosclerosis, which can affect various arterial vessels within the body, narrow them, and manifest itself in both acute and chronic forms. Among acute conditions are myocardial infarction (MI), stroke, acute mesenteric ischemia, acute peripheral arterial occlusion, or even thoracic aorta rupture. The chronic group encompasses, amongst others, recurrent transient ischemic attacks (TIAs), stable angina, aortic aneurysm, worsening renal functioning, or chronic limb ischemia [2]. Atherosclerosis develops through three consecutive phases, starting from the lipid-streak phase, via the fibrous plaque phase, to the final phase, namely, advanced lesions with thrombosis. At the outset, lipids are retained and trapped inside the intima of the arterial wall, leading to macrophage infiltration and the absorption of surplus lipids, resulting in foam cells formation. The next phase entails the passage of vascular smooth muscle cells (VSMC) to establish a durable fibrous cap, covering the atherosclerotic area. Overabundance of foam cells, however, results in necrosis inside the plaques and triggers the necrotic core formation. As it grows, the fibrous cap may rupture and expose the necrotic core, bringing it into contact with blood, thereby provoking thrombosis [3]. Different types of plaques vary in their susceptibility to rupture. The propensity for rupture primarily depends on the composition of the atherosclerotic plaque itself. Inflammatory, lipid-rich plaques appear to be decidedly more prone to rupture than those covered by a

thick fibrous cap. Of course, the size of the lesions also matters, although it holds secondary significance compared to their structure [4]. Undoubtedly, the primary, although not sole, factor contributing to atheromatous plaques formation is the elevated level of low-density lipoprotein cholesterol (LDL-C) in the bloodstream [5]. The level of LDL-C is particularly elevated in familial hypercholesterolemia (FH), which results in a significant acceleration of ASCVD development [6]. Other diseases significantly contributing to the development of ASCVD include hypertension and diabetes mellitus (DM) [7]. DM also contributes to the development of another pathology significantly impacting atherosclerosis, namely, the development of diabetic nephropathy. This condition, in turn, can decrease glomerular filtration rate (GFR) and may result in chronic kidney disease (CKD), even leading to end-stage renal disease (ESRD) [8]. CKD, in turn, is responsible for the retention of uremic toxins, increased oxidative stress, vascular calcification, and notably, chronic inflammation. All of these factors exacerbate the progression of ASCVD [9]. Particularly, the role of inflammation is increasingly emphasized in the context of the pathogenesis of atherosclerosis [10]. The correlation between chronic inflammatory state and increased frequency of premature atherosclerosis becomes evident, among others, in individuals suffering from rheumatoid arthritis [11]. Similarly, in individuals with viral hepatitis C, an increased frequency of ASCVD complications has been observed [12]. However, the etiology is even more intricate. It appears that disruptions within the gut microbiota can also play a significant role in the pathogenesis of this entity. Bacteria inhabiting the gastrointestinal tract produce metabolites that subsequently participate in cholesterol homeostasis [13]. In the context of ASCVD etiology, one cannot overlook the role of factors such as obesity, inadequate diet, sleep deprivation, air pollution, active and passive smoking, and a lack of physical activity [14,15]. It has also been noted that atherosclerosis affecting coronary arteries typically manifests more prominently in men than in women [16].

Selected risk factors for atherosclerosis are depicted in Figure 1. Moreover, given the complexity, prevalence, and risk associated with this disease, our review delves into the topic of biomarkers and modern treatment approaches.



**Figure 1.** Selected disease entities and other risk factors contributing to the development and progression of ASCVD [6,7,9,13–15]. ASCVD—atherosclerotic cardiovascular disease; CKD—chronic kidney disease; DM—diabetes mellitus; FH—familial hypercholesterolemia.

## 2. Selected Biomarkers

Atherosclerosis is defined as a persistent inflammatory condition of the artery wall [17]. Neo-angiogenesis is significantly engaged in plaque instability, resulting in plaque rupture. Vascular endothelial growth factor (VEGF), which promotes cell proliferation, inhibits apop-

toxicity, increases vascular permeability, vasodilation, and recruits inflammatory cells to the injury site, contributes to the development of atherosclerosis and worsens cardiovascular disease (CVD) [18]. The landscape of cardiovascular research is rapidly advancing, with the quest to pinpoint and authenticate biomarkers for atherosclerosis taking center stage. This pursuit is driven by the promise that such biomarkers hold not only for deepening our grasp of the disease's intricate biological foundations but also for steering individualized treatment approaches. Among the myriad biomarkers scrutinized, those linked to inflammation, lipid metabolism, and genetic predispositions stand out for their capacity to foretell the development and escalation of atherosclerosis [19]. Particularly, C-reactive protein (CRP) has emerged as a key inflammatory biomarker, its elevated levels closely correlating with an increased risk of cardiovascular events. This correlation underscores the critical role of inflammation in the progression of atherosclerosis. Findings from recent investigations reveal that intensive statin therapy can significantly reduce both LDL cholesterol and CRP levels, leading to a marked decrease in cardiovascular incidents and mortality rates. The most pronounced benefits of such treatment were observed in individuals who achieved the lowest levels of LDL cholesterol and CRP, highlighting the dual importance of managing cholesterol levels and inflammatory processes in cardiovascular risk reduction. Yet, it is important to note that the decrease in CRP levels following statin therapy may reflect a reduction in LDL-induced inflammatory activity within atherosclerotic plaques, rather than a direct effect on the CRP pathway itself [20]. High-sensitivity C-reactive protein (hsCRP), while a recognized indicator of CVD risk, especially following acute coronary syndrome (ACS), has evolved into a metric of residual inflammatory cardiovascular risk, akin to the role played by LDL-C. This evolution expands the understanding of cardiovascular risk to include inflammatory factors. Despite the acknowledged clinical relevance of hsCRP, its role as a potential target for specific anti-inflammatory treatments remains debated. Consequently, research has also explored other inflammatory mediators, positioning hsCRP more as a marker of underlying inflammation rather than a direct target for therapy. This nuanced approach to cardiovascular risk assessment and management underscores the complexity of atherosclerosis as a disease influenced by both lipid accumulation and inflammatory processes [21].

### 2.1. Inflammasome and Cytokines

The NOD-like receptor protein 3 (NLRP3) inflammasome participates in the development of AH [22]. DAMPs (damage-associated molecular patterns), such as LDL, cholesterol crystals, calcium pyrophosphate crystals, uric acid crystals, hyperglycemia, disrupted blood flow, and hypoxia [23], activate the NLRP3 inflammasome, which produces interleukin-1 $\beta$  (IL-1 $\beta$ ) via caspase-1-mediated cleavage of pro-IL-1 $\beta$ . The NLRP3 inflammasome is a multimeric cytosolic protein complex composed of pathogen-associated molecular patterns (PAMPs), DAMPs, and neutrophil extracellular traps (NETs) [24], which are pro-atherosclerotic, cytotoxic, nucleus-derived, and net-like chromatin structures released extracellularly. In response to infections and inflammatory stimuli such as cholesterol crystals, oxidized low-density lipoprotein (oxLDL), oxysterols, platelets, and chemokines, neutrophils release cytosolic and nuclear material, forming a net-like extracellular structure [25]. This also activates the NLRP3 inflammasome [26]. During pyroptosis, the NLRP3 inflammasome generates IL-1 $\beta$  and IL-18, which are strong systemic inflammatory mediators. IL-1 $\beta$  stimulates the production of both itself and IL-6. IL-1 $\beta$  is initially generated as pro-IL-1 $\beta$ , which is then cleaved into its active form by caspase-1 once the NLRP3 inflammasome is activated [27]. IL-1 $\beta$  has autocrine, paracrine, and endocrine actions and is linked to the development of autoinflammatory illnesses, gout, diabetes, atherosclerosis, and neurodegenerative disorders. IL-1 $\beta$  stimulates its own synthesis, along with that of IL-6, which is a hormone-like cytokine that contributes to innate and adaptive immunity and has both pro- and anti-inflammatory characteristics. Production of IL-6 takes place in T cells, which are the primary producers of IL-6, as well as monocytes, fibroblasts, and endothelial cells [28]. Apart from inflammation, IL-6 plays a metabolic role, regulating lipid

metabolism and insulin resistance [27]. IL-6 also interacts with soluble or membrane-bound receptors, as well as glycoprotein 130 (gp130), forming a hexameric complex. When a receptor is activated, intracellular signaling begins via the Janus kinase and signal transducer and activator of transcription (JAK-STAT) pathways, eventually leading to target gene transcription. This causes both local and systemic inflammation, which results in disruption of the balance of regulator and effector T and B cells, as well as immunoglobulin and acute-phase protein synthesis [29]. In turn, IL-6 stimulates the liver to produce acute phase reactants such as plasminogen activator inhibitor-1 (PAI-1) and fibrinogen, both of which have thrombogenic qualities. In addition, IL-6 stimulates apolipoprotein(a) [apo(a)] production by activating the LPA gene's promoter region. Other variables that can activate IL-6 include TNF (tumor necrosis factor), toll-like receptors, prostaglandins, adipokines, and stress. During acute inflammation, IL-6 increases the hepatic production of several acute-phase proteins, including fibrinogen, PAI-1, serum amyloid A (SAA), and CRP, which are implicated in host immunological responses as well as thrombogenesis. It is worth noting that patients with COVID-19 have a higher risk of MACE due to IL-6 [30]. Persistently high IL-6 levels lead to chronic inflammation and, ultimately, tissue damage. CCs, the primary causes of atherosclerosis, are currently regarded as the most critical trigger for NLRP3 inflammasome activation. This event is undesirable because it can cause lipid peroxidation and affect the physiological activity of bio enzymes. Oxidized phospholipids are known to promote inflammation. As a result, oxLDLs are used as a clinical indicator of plaque inflammation. The mechanisms of endothelial dysfunction reveal that inflammatory factors play an important role in the pathophysiology of this condition [31]. Modified lipids cause the intima's inflammatory cells to release chemokines and cytokines such as TNF $\alpha$ , IL-1, -4, and -6, and interferon-gamma. These chemokines and cytokines subsequently activate additional leukocytes, endothelial cells, and adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1) [32]. These altered lipoproteins contribute to the formation of atherosclerotic plaques. LDL's cholesterol-rich lipoproteins are absorbed and integrated into macrophages, and they also produce ROS and reactive nitrogen species (RNS), pro-oxidants that contribute to the development of atherosclerosis. Increased amounts of ROS may be induced by reduced mitochondrial activity, which is associated with aging. The mechanisms of endothelial dysfunction reveal that inflammatory factors play an important role in the pathophysiology of this condition. The intima of a damaged arterial wall is rich in lymphocytes and mast cells [33]. Modified lipids cause the intima's inflammatory cells to release chemokines and cytokines such as TNF $\alpha$ , interleukin-1, -4, and -6, and interferon-gamma. These chemokines and cytokines subsequently activate additional leukocytes, endothelial cells, and adhesion molecules, including VCAM-1. These altered lipoproteins contribute to the formation of atherosclerotic plaques. LDL's cholesterol-rich lipoproteins are absorbed and integrated into macrophages, and they also produce ROS and RNS, pro-oxidants that contribute to the development of atherosclerosis. Increased ROS levels might be driven by decreased mitochondrial activity, which is linked to aging [31]. OxLDLs agitate endothelial cells, increasing the production of adhesion-forming chemicals. The ROS and RNS convert LDL-C into ox-LDLs, which form part of the intimal layer [33]. Atherosclerosis begins with the subendothelial retention of ApoB 100, which contains lipoproteins. LDL penetration across a defective endothelium involves a number of variables. The process can be divided into three phases: commencement, progression, and thrombosis. The intima is bordered by a single layer of endothelial cells known as the endothelium and a subendothelial extracellular matrix, which is composed of collagen and elastin. Endothelium regulates vascular tone, coagulation, and maintains vascular homeostasis through highly controlled systems, including nitric oxide, prostacyclin, and endothelin-1 [34]. Tunica media include a large number of smooth muscle cells (SMCs), which are organized concentrically inside an elastin-rich cellular matrix to store the kinetic energy necessary for pulsatile flow transmission. The adventitia is made up of mast cells, fibroblasts, and a proteoglycan and collagen-rich matrix. The internal and external elastic laminae divide the intima, media, and adventitia, respectively. Nonetheless, the artery is

damaged by the interaction of Ox-LDL and other risk factors, hardening and narrowing the lumen, resulting in disrupted blood flow [5]. Fibrinogen has been established as a significant independent risk factor for CVD. Fibrinogen has also been linked to classic cardiovascular risk factors, implying that fibrinogen elevation might be a mechanism by which these risk factors work. There are various ways in which fibrinogen might raise cardiovascular risk. First, it attaches to active platelets via glycoprotein IIb/IIIa, which promotes platelet aggregation [35]. Second, higher fibrinogen levels encourage fibrin production. Third, it makes a significant contribution to plasma viscosity. Finally, it is an acute-phase reactant that increases in inflammatory conditions [36].

### 2.2. Fibroblast Growth Factor-23

Fibroblast growth factor-23 (FGF-23), a hormonal activator of urinary phosphate excretion, rises in blood concentration during early CKD [37]. FGF-23's activities are mainly restricted to organs that express the coreceptor Klotho, notably the renal tubules, where it inhibits sodium phosphate cotransporters. Animal studies indicate direct (i.e., Klotho-independent) [38] cardiotoxicity, leading to suggestions that FGF-23 should be viewed not just as a marker for CVD but also as a causative contributing element. A meta-analysis of traditional epidemiological research revealed independent relationships between greater circulating FGF-23 concentrations and an increased risk of atherosclerotic cardiovascular illnesses (MI and stroke) and heart failure (HF). However, there is significant ambiguity about causation because these relationships lack a strong "exposure-response" link and are non-specific; there are additional reports of positive correlations between FGF-23 and infection, fractures, acute kidney injury (AKI), and all-cause mortality [16]. Thus, residual confounding remains a plausible explanation for these FGF-23 relationships [39]. Naturally occurring genetic variations (single nucleotide polymorphisms [SNPs]) related with biological features are assigned at random during conception and can be utilized as tools in genetic epidemiology studies. This Mendelian randomization (MR) strategy can overcome some of the constraints inherent in traditional observational studies [40], and it is especially useful when attempting to account for confounding by kidney function. Previous MR investigations of FGF-23 have been hampered by low power since the genetic variations employed explain only about 3% of the diversity in FGF-23, and they have not studied the breakdown of correlations with atherosclerotic versus non-atherosclerotic phenotypes [38].

### 2.3. GDF-15

In atherosclerosis, which is a chronic inflammatory condition characterized by the monocytes activity in lipid deposition within vessel walls [41]. These monocytes, upon ingestion of lipoproteins like oxLDLs, transform into macrophages and give rise to foam cells. Notably, there exists a reciprocal relationship between oxLDLs and growth and differentiation factor-15 (GDF-15): oxLDLs stimulates GDF-15 production in macrophages, while GDF-15 inhibits lipid accumulation induced by oxLDL and modulates the pro-inflammatory cytokine profile of vessel wall macrophages. GDF-15 also influences lipid metabolism, crucial in atherosclerosis, by reducing lipid accumulation and foam cell formation, potentially through activation of the peroxisome proliferator-activated receptor  $\beta/\delta$  (PPAR $\beta/\delta$ ) pathway [42].

Moreover, GDF-15 appears to influence lipid synthesis independently of oxLDL in human macrophages, suggesting a novel role in atherosclerotic plaque formation and progression by disrupting autophagic processes, impacting lipid homeostasis. While these findings suggest a potential atheroprotective effect of GDF-15, clinical studies have linked it to increased cardiovascular event risk and mortality in individuals with established ASCVD. GDF-15 contributes to both the onset and advancement of atherosclerosis [37,42].

Studies investigating GDF-15 in coronary artery disease (CAD) have shown its potential as a predictive biomarker for acute coronary syndrome (ACS) recurrence, MI-related complications, HF, and mortality. In combination with N-terminal pro-B-type natriuretic

peptide (NT-proBNP), GDF-15 can identify high-risk patient groups. Furthermore, research on the relationship between GDF-15 and coronary artery calcium score (CACS) indicates a significant positive correlation, highlighting its potential as a diagnostic marker in CAD [42].

#### 2.4. Exosomes

Exosomes (EX) are extracellular vesicles that originate within the endosomes of eukaryotic cells [43]. These vesicles comprise a diverse array of molecules, characterized by their aqueous core surrounded by a lipophilic membrane. The biosynthesis of EX involves the incorporation of proteins, DNA, RNA, and lipids from the donor cell's membrane into the multivesicular bodies, subsequently leading to the formation of EX. This process culminates in the secretion of EX upon fusion with the parent cell's membrane [44]. Notably, exosomes are distinguished by their significant content of microRNAs (miRNA) [45], alongside substantial quantities of long non-coding RNAs (lncRNA) and circular RNAs (circRNAs) [46]. These nucleic acid components have been implicated in the pathogenesis of atherosclerosis, highlighting the pivotal role of exosomes in cellular communication and disease progression.

##### 2.4.1. miRNA

As discussed above, platelet activation and endothelial damage play essential roles in atherosclerosis pathogenesis. With the usage of immunohistochemistry and western-blotting technique, Li et al. established that the levels of miRNA-223, miRNA-339, and miRNA-21 were elevated in thrombin-activated platelet exosomes. Additionally, miRNA-223 was established to be a key player in the inhibition of the phosphorylation of p38 mitogen-activated protein kinases (p38), c-Jun N-terminal kinases (JNKs), and extracellular signal-regulated kinases (ERK) and blocked the nuclear translocation of NF- $\kappa$ B p65. Furthermore, the miR-223 inhibitor blocked the down-regulating effects of exosomes on ICAM-1 expression [47]. The MAPK pathway, encompassing ERK1/2, JNK, and p38 MAPK, represents a fundamental signaling mechanism that connects cell surface receptors to critical regulatory targets within the cell, showcasing its evolutionary conservation and versatility. This pathway is pivotal in orchestrating the inflammatory response, becoming activated in response to a plethora of stimuli such as oxidative stress, cytokines, and growth factors. These stimuli are particularly abundant within the milieu of atherosclerotic lesions, indicating the pathway's crucial role in the disease's progression. The interaction between miRNAs and the MAPK pathway elucidates a sophisticated regulatory network, where miRNAs not only modulate the activity of this pathway but also influence the overall inflammatory environment characteristic of atherosclerosis. Such insights into the molecular dynamics of atherosclerosis offer promising avenues for the development of targeted therapies aimed at mitigating the inflammatory processes at the heart of this CVD [48].

miRNAs derived from exosomes, isolated seamlessly from various fluids, represent a leap forward in biomarker development for diseases like atherosclerosis. Their superiority over circulating miRNAs stems from the ability to purify exosomes from specific cell types, thereby enhancing the biomarker's sensitivity and specificity [49]. Recent studies have illuminated the promise of specific exosomal miRNA profiles, such as miR-122-5p, miR-27b-3p, and miR-101-3p, in forecasting recurrent ischemic events in cases of intracranial atherosclerosis [50]. Furthermore, the detection of certain exosomal miRNAs, including miR-92a-3p and miR-30e, has been linked to atherosclerotic conditions, suggesting their utility in diagnosing and managing coronary atherosclerosis [51,52]. While these findings underscore the diagnostic and prognostic potential of exosomal miRNAs in atherosclerosis, the transition of these biomarkers into clinical practice awaits further validation in extensive cohort studies and the standardization of isolation methods as per international guidelines.

#### 2.4.2. lncRNA

lncRNAs have garnered significant attention for their pivotal roles in regulating essential cellular mechanisms. Characterized by their length of over 200 nucleotides and possessing mRNA-like features such as 5' capping, splicing, and polyadenylation, lncRNAs have demonstrated their capacity to interact with various molecular entities, including RNA, DNA, proteins, and RNA-binding proteins [53]. Among these, the macrophage-specific lncRNA MAARS (macrophage-associated atherosclerosis lncRNA aequence) has emerged from RNA-seq profiling of the intima of lesions, revealing a remarkable 270-fold increase in expression in the aortic intima during atherosclerotic progression and a 60% decrease upon regression. Intriguingly, MAARS knockdown in LDLR<sup>-/-</sup> mice leads to a 52% reduction in atherosclerotic lesion formation, a process that is largely independent of lipid profiles and inflammatory responses. Instead, this reduction is attributed to decreased macrophage apoptosis and enhanced efferocytosis within the vessel wall. The interaction between MAARS and HuR/ELAVL1, a key RNA-binding protein involved in apoptosis regulation, underscores MAARS's crucial role in macrophage survival mechanisms, further affecting the expression of significant apoptosis and cell-cycle regulators such as p53, p27, Caspase-9, and BCL2 through HuR cytosolic shuttling [54].

Additionally, the landscape of lncRNAs in vascular biology is further enriched by the discovery of lncRNA NEXN-AS1, which influences endothelial cell activation and monocyte adhesion through the TLR4/NF- $\kappa$ B signaling pathway, acting as a deterrent to atherogenesis [55]. Moreover, lncRNA CCL2 is highlighted for its contribution to human atherosclerosis by upregulating CCL2 mRNA levels in endothelial cells, pointing to a complex network of lncRNA-mediated regulation in the vascular system [56]. These discoveries not only elucidate the multifaceted roles of lncRNAs in vascular disease states but also pave the way for innovative therapeutic strategies targeting these non-coding RNAs to combat atherosclerosis and related conditions.

#### 2.4.3. circRNA

Circular RNAs (circRNAs) represent a novel class of RNA molecules characterized by their unique closed-loop structure, resulting from a process known as back-splicing, where a covalent bond links the ends of linear RNA sequences [57]. These non-coding RNAs play crucial roles in the regulatory mechanisms governing protein transcription, functionality, and even the translation process leading to polypeptide formation [57]. An array of research endeavors has delved into the exploration of circRNAs, with six *in vitro* studies shedding light on the upregulation of circCHFR within atherosclerotic conditions, achieved through the stimulation of cells using oxLDL or PDGF. This upregulation has been linked to the sponging of miRNAs and the overexpression of genes conducive to atherosclerotic processes. For example, the sequestration of miR-370 was observed to enhance the expression of FOXO1/Cyclin D1, thus promoting the proliferation and migration of VSMCs [58]. In contrast, research conducted by Zhang W-B et al. revealed diminished levels of circHIPK3 in both the serum and tissues of patients with atherosclerosis, correlating with increased osteogenic and chondrogenic differentiation, as well as elevated mineralization and calcium deposition in VSMCs *in vitro*. Notably, the overexpression of circHIPK3 was found to engage in miR-106a-5p sponging, leading to the activation of the MFN2 gene. This activation played a pivotal role in mitigating osteogenic and chondrogenic differentiation, thereby reducing calcium buildup in VSMCs [59–62].

#### 2.5. Immune Cells

Mast cells have been confirmed to exist within atherosclerotic lesions, with studies demonstrating their ability to initiate the phosphorylation of p38 MAPK upon stimulation by oxLDL under laboratory conditions [63]. OxLDL plays a critical role as a pro-inflammatory and pro-atherogenic agent, impacting all phases of atherosclerosis by promoting the release of cytokines and chemokines in macrophages, VSMCs, and endothelial cells [64]. Furthermore, clinical research has highlighted the significance of serum


oxLDL levels as a key indicator for the severity of acute coronary syndrome. Notably, research by Huang et al. that focused on younger patients, specifically those under 55 years of age, demonstrated in a study involving 128 CAD patients that oxLDL is a significant risk factor for the onset of atherosclerosis, independent of smoking, hypertriglyceridemia, and the ApoB/ApoA1 ratio. The level of oxLDL was significantly higher in the CAD group than in control ( $p < 0.01$ ) [65]. Additionally, it was found that serum levels of oxLDL are affected by smoking habits, with smoking noted to increase these levels [66]. Therefore, the serum level of oxLDL might be a valuable independent atherosclerosis predictor in the younger population.

T lymphocytes play a critical role in the progression of atherosclerosis, with their association observed in calcific nodules within the fibrous cap and the plaque itself [67]. These cells infiltrate lesions at an early stage, likely drawn by pro-inflammatory cytokines released by macrophages, smooth muscle cells (SMCs), and valvular interstitial cells (VICs), and their migration into the tissue is aided by adhesion molecules like VCAM-1, ICAM-1, and P-selectin on activated endothelial cells. As the disease progresses, neo-angiogenesis offers additional pathways for T lymphocyte infiltration [68]. The involvement of diverse T cell subsets, including CD4+ helper and CD8+ cytotoxic T cells, in atherosclerosis is well-documented [68,69]. Notably, these subgroups exhibit dual roles in disease progression, serving as both pro- and antiatherogenic factors, which positions them as potential biomarkers for atherosclerosis. TH1 cells, a subtype of T helper cells, are particularly significant for being the most common T cells in atherosclerotic plaques and are known to exacerbate inflammation and plaque instability [70]. This is supported by findings that a genetic deficiency in the TH1-specific transcription factor TBX21 or IFN- $\gamma$  reduces atherosclerosis in hyperlipidemic mice, underscoring their pro-atherogenic influence [71,72]. On the other hand, TH17 cells, activated by IL-17, are implicated in plaque development, with studies showing a decrease in aortic plaque formation in IL-17 deficient mice, highlighting the complexity of T cell roles in atherosclerosis [73]. The exact impact of CD8+ T cells remains elusive, with some evidence pointing to a pro-atherogenic role in the early stages of plaque development, yet definitive conclusions about their overall contribution to atherosclerosis are still being explored [74,75].

The complex interplay between immune responses and atherosclerosis is significantly influenced by the roles of natural killer T (NKT), which interact with lipid antigens and chemokines within atherosclerotic environments. NKT cells, known for their ability to identify lipid antigens presented on CD1d molecules by antigen-presenting cells, are implicated in the aggravation of atherosclerosis [76]. Their presence is notably marked in atherosclerotic lesions where they contribute to inflammation through the secretion of cytokines and engage in processes like neo-angiogenesis, which destabilizes plaques [77]. This involvement is primarily due to their secretion of granzyme B, perforin, and IL-8, the latter of which promotes angiogenesis through the induction of EGFR in endothelial cells [78]. The exacerbation of atherosclerosis by NKT cells is evidenced in studies utilizing ApoE $^{-/-}$  mouse models, demonstrating the cells' pro-atherogenic activities and their contribution to disease progression in cardiovascular tissues [79].

The exploration of NKT cells has expanded to understand their activation by both endogenous self-lipid and exogenous microbial lipid antigens. This activation prompts a swift cytokine and cytotoxic protein response, pivotal in the pathogenesis of atherosclerosis. The modulation of NKT cell activity by gut microbiota illustrates the dynamic interaction between host immunity and microbial factors in cardiovascular disease. Parallel to NKT, cells are attracted and activated by specific chemokines such as MCP-1 and fractalkine. These chemokines not only facilitate NKT cell migration into the lesion site but also enhance their cytotoxic function and IFN- $\gamma$  production, further promoting a pro-atherogenic environment. The cytokines capable of recruiting and activating NK cells, including IL-15, IL-12, IL-18, and IFN- $\alpha$ , have been identified to contribute to atherosclerosis, highlighting the integral role of NK cells in the disease's development [80]. This comprehensive view underscores the critical contribution of NKT cells to the inflammatory processes central to

atherosclerosis. By delineating the pathways through which these cells influence disease progression, research continues to unravel the potential for targeted interventions aimed at modulating immune cell activity in atherosclerosis [81]. The inflammatory cascade of markers has been shown at Figure 2 [41,50,80].



**Figure 2.** Inflammatory cascade of markers [41,50,80]. IL-1 $\alpha$ —interleukin 1 $\alpha$ ; IL-18—interleukin 18; IL-1 $\beta$ —interleukin 1 $\beta$ ; CRP—C-reactive protein; Th-1—type 1 helper T-cell; Th-reg—regulatory T-cell; TNF- $\alpha$ —tumor necrotic factor  $\alpha$ ; IL-2—interleukin 2; INF- $\gamma$ —interferon  $\gamma$ ; IL-10—interleukin 10; TGF- $\beta$ —transforming growth factor  $\beta$ ; GDF-15—growth differentiation factor 15.

### 3. Treatment Possibilities

#### 3.1. Statins and Ezetimibe

Over the past three decades, statins have played a significant role in preventing numerous cardiovascular events associated with atherosclerosis and reducing cardiovascular mortality [82]. Statins function by reducing the amount of cellular cholesterol through targeted inhibition of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase. This inhibition curtails the synthesis of cholesterol, consequently diminishing hepatic cholesterol levels. As a result, there is an upregulation of LDL-receptors on the membranes of liver cells, facilitating the removal of LDL-C particles from the bloodstream [83]. Additional effects of statins, which are not completely elucidated but are noteworthy, include LDL-independent actions, also known as pleiotropic effects. They are shown in the Table 1 below [84–86].


The American Heart Association Guidelines divide statin therapy into three categories based on the intensity: high-intensity, moderate-intensity, and low-intensity. Various ethnic or racial groups have demonstrated differing sensitivities to similar statin doses; for example, Asians may be more sensitive to the effects of statins [87]. A prospective, randomized, single-blind clinical trial was conducted to compare the lipid-lowering effect of statins (5 mg rosuvastatin), placebo, and six dietary supplements (fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice). After 28 days, the decrease in LDL-C levels among these participants was examined, and the results were compared. The reduction in LDL-C percentage with rosuvastatin significantly exceeded that of all supplements and the placebo (the reduction in comparison to placebo was 35.2%) [88]. A meta-analysis published in JAMA demonstrated that both statin therapy and non-statin therapies, which

regulate LDL receptor (LDLR) expression to lower LDL-C, show similar relative risks of major vascular events per change in LDL-C. Furthermore, lower levels of achieved LDL-C were linked with decreased rates of major coronary events. Furthermore, the European Society of Cardiology presented a paper stating that statin therapy in individuals without a history of CVD may lead to a 15% decrease in the risk of death from vascular causes for every 1 mmol/L reduction in LDL cholesterol [89,90]. Long-term use of statins can result in a range of adverse effects. Statin toxicity or intolerance mostly manifests as SAMs (statin-associated muscle symptoms). These symptoms are shown in the Figure 3 below [91].

**Table 1.** Pleiotropic effects of statins [84–86].

Effect	Mechanism
Anti-inflammatory	Reduction in CRP, IL-1 $\beta$ , TNF- $\alpha$ Decrease in leukocyte–endothelial cell adhesion
Plaque reduction/stabilization	Increased thickness of fibrous cap Macrocalcification
Reduced oxidative stress	Reduced ROS
Reduction of platelet aggregation	Decreased platelet reactivity Decreased TXA2 synthesis
Improved vascular tone	Increased NO
	Reduced SMC activation, proliferation

CRP, C-reactive protein; IL-1 $\beta$ , interleukin-1 $\beta$ ; TNF, tumor necrosis factor; ROS, reactive oxygen species; TXA2, thromboxane A2; NO, nitric oxide; SMC, smooth muscle cell.



**Figure 3.** Side effects of statins classified as SAMs [91]. SAMs, statin-associated muscle symptoms; CK, creatinine kinase.

Another medication used to reduce LDL levels frequently mentioned in conjunction with statins is ezetimibe. Ezetimibe is an inhibitor of Niemann–Pick C1-Like 1 (NPC1L1), acting to block the absorption of cholesterol at the brush border of the small intestine, and it has proven an effective and usually well-received choice in treating hypercholesterolemia [91]. Incorporating ezetimibe with a statin has been demonstrated to help more patients achieve cholesterol levels recommended by guidelines and permits the utilization of lower doses of statins. This could be especially advantageous for individuals susceptible to the dose-related side effects of statins. Recent findings suggest that combinations of

statins and ezetimibe are increasingly recognized for their ability to decrease the risk of major atherosclerotic events by an extent comparable to that observed with statins alone, even when achieving similar absolute reductions in LDL-C levels [92]. One of the studies analyzing the effect of ezetimibe with a statin was the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). IMPROVE-IT was a double-blind, controlled trial involving 18,144 high-risk patients who had experienced stabilized ACS. Participants were randomly allocated to two groups: one receiving a combination of simvastatin 40 mg and ezetimibe 10 mg; and the other receiving simvastatin 40 mg alone. The occurrence of cardiovascular events among subjects was analyzed and proved to be reduced among patients taking simvastatin with ezetimibe [93,94]. A meta-analysis of 12 randomized, controlled trials was conducted to assess the effectiveness of ezetimibe in reducing LDL-C levels in individuals with ASCVD. The use of combination ezetimibe plus statin therapy demonstrated a greater absolute reduction in LDL-C levels compared to statin monotherapy. Therefore, it can be inferred that adding ezetimibe to statin therapy resulted in a modest additional reduction in LDL-C.

### 3.2. PCSK9 Inhibitors

In recent years, PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors have emerged as a promising therapeutic option for managing ASCVD. PCSK9 is a protein produced primarily in the liver, where it plays a crucial role in regulating LDLR degradation. Elevated levels of PCSK9 lead to increased degradation of LDLRs, resulting in reduced LDL-C clearance from the bloodstream and elevated LDL-C levels [95]. PCSK9 inhibitors, like evolocumab (Repatha) and alirocumab (Praluent), are monoclonal antibodies that bind to PCSK9, preventing its interaction with LDLRs and subsequently increasing LDLR expression on the surface of hepatocytes [96,97]. This mechanism leads to enhanced LDL-C clearance and lowered LDL-C levels in the bloodstream [98]. Numerous clinical trials have demonstrated the efficacy of PCSK9 inhibitors in reducing LDL-C levels and improving cardiovascular outcomes in patients with ASCVD [99]. Trials such as FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) and ODYSSEY OUTCOMES evaluated the cardiovascular benefits of evolocumab and alirocumab, respectively, in high-risk patients with established ASCVD. The FOURIER trial was a landmark study investigating the cardiovascular benefits of evolocumab in patients with established ASCVD. A total of 27,564 participants were enrolled and followed for a median of 2.2 years. In the FOURIER trial (multicenter, randomized, double-blind, placebo-controlled), treatment with evolocumab resulted in a significant reduction in LDL cholesterol levels by approximately 59%, compared to placebo. Additionally, the study found that evolocumab lowered the risk of major adverse cardiovascular events (MACE) by 15% over a median follow-up period of 2.2 years. These findings underscore the substantial cardiovascular benefits associated with PCSK9 inhibition in patients with established ASCVD [100,101]. In the ODYSSEY OUTCOMES trial (multicenter, randomized, double-blind, placebo-controlled trial), treatment with alirocumab led to a substantial reduction in LDL cholesterol levels by approximately 61% compared to placebo. Furthermore, alirocumab demonstrated a significant reduction in the risk of major adverse cardiovascular events (MACE), including MI, stroke, and cardiovascular death, by 15% over a median follow-up period of 2.8 years. These results provide robust evidence for the efficacy of PCSK9 inhibitors in reducing cardiovascular risk in patients with recent ACS [102,103]. Based on compelling evidence from clinical trials, major cardiovascular guidelines have incorporated PCSK9 inhibitors into their recommendations for ASCVD management. These guidelines endorse the use of PCSK9 inhibitors in specific patient populations, such as those with established ASCVD who require further LDL-C lowering despite maximally tolerated statin therapy, or in individuals with FH who cannot achieve LDL-C goals with traditional lipid-lowering therapies alone [100]. Overall, PCSK9 inhibitors have demonstrated a favorable safety profile in clinical trials, with adverse events similar to placebo. Common side effects include muscle pain, back pain, nasopharyngitis or headache [104]. One of

the primary challenges associated with PCSK9 inhibitors is their cost, which has raised concerns regarding affordability and accessibility for patients and healthcare systems [105].

### 3.3. Bempedoic Acid

As an inhibitor of ATP citrate lyase (ACL), bempedoic acid offers a novel mechanism of action to reduce LDL-C levels and mitigate cardiovascular risk [106]. Bempedoic acid, previously known as ETC-1002, is an oral, once-daily medication that inhibits ACL, an enzyme involved in cholesterol synthesis. By blocking ACL, bempedoic acid reduces the production of cholesterol precursors, leading to decreased hepatic cholesterol synthesis and subsequent lowering of LDL-C levels [107]. Unlike statins, which act on HMG-CoA reductase, bempedoic acid operates upstream in the cholesterol biosynthesis pathway, offering an alternative therapeutic strategy for LDL-C reduction [108,109]. The efficacy of bempedoic acid in reducing LDL-C levels and improving cardiovascular outcomes has been demonstrated in several clinical trials [110]. The CLEAR Harmony and CLEAR Wisdom trials were randomized, double-blind, placebo-controlled phase 3 clinical trials investigating the safety and efficacy of bempedoic acid in patients with hypercholesterolemia and a high risk of CVD [111,112]. In the CLEAR Harmony trial, over 2200 patients were enrolled and randomized to receive either bempedoic acid or placebo in addition to maximally tolerated statin therapy. The trial demonstrated that treatment with bempedoic acid led to a significant reduction in LDL cholesterol levels by approximately 18% compared to placebo at 12 weeks [111]. Similarly, in the CLEAR Wisdom trial, which enrolled over 1800 patients, treatment with bempedoic acid resulted in a significant reduction in LDL cholesterol levels by approximately 17% compared to placebo at 12 weeks. Bempedoic acid was well tolerated in both trials, with adverse events similar to placebo [112]. The compelling findings from the trials have contributed to the regulatory approval of bempedoic acid by the United States Food and Drug Administration (FDA). In February 2020, the FDA approved bempedoic acid (Nexletol) as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established ASCVD who require additional LDL-C lowering [113,114]. Bempedoic acid is recommended in patients with ASCVD who require additional LDL-C lowering beyond statin therapy or in those who cannot tolerate statins [113]. Notably, bempedoic acid does not appear to increase the risk of adverse events such as muscle-related side effects or liver enzyme elevations typically associated with statin therapy [115]. Unfortunately, as newer medication, the cost of bempedoic acid may present a barrier to access for some patients [116].

### 3.4. Inclisiran

Inclisiran is a first-in-class small interfering RNA (siRNA) therapy designed to selectively target and inhibit PCSK9 messenger RNA (mRNA) in the liver. It specifically binds to N-acetylgalactosamine (GalNAc) and the asialoglycoprotein receptor (ASGPR) [117]. By silencing PCSK9 expression, inclisiran promotes the upregulation of hepatic LDLRs, leading to increased clearance of LDL-C particles from the bloodstream. This unique mechanism of action offers a promising approach to lowering LDL-C levels and reducing cardiovascular risk in patients with ASCVD [118]. Clinical trials, including the ORION program, have demonstrated the efficacy and safety of inclisiran in reducing LDL-C levels in patients with ASCVD or FH [119]. The ORION program consists of a series of clinical trials evaluating the efficacy, safety, and tolerability of inclisiran across diverse patient populations. The pivotal trials in the ORION program, including ORION-9 (Trial to Evaluate the Effect of Inclisiran Treatment on LDL-C in Subjects With HeFH), ORION-10 (Inclisiran for Participants With ASCVD and Elevated LDL-C), and ORION-11 (Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated LDL-C), demonstrated consistent and robust reductions in LDL-C levels with inclisiran therapy [120]. The ORION trials evaluated inclisiran's efficacy when administered as a subcutaneous injection every 6 to 12 months. In these trials, inclisiran achieved substantial and durable reductions in LDL-C levels of

up to 50%, surpassing those achieved with standard lipid-lowering therapies. Moreover, inclisiran exhibited a favorable safety profile, with minimal adverse effects observed across multiple studies [121,122]. Inclisiran (Leqvio) has received approval from both the FDA and the European Medicines Agency (EMA), in combination with dietary adjustments and the highest tolerated dosage of statin therapy, for adults diagnosed with HeFH or ASCVD necessitating further reduction in LDL cholesterol levels [123–125]. However, various factors should be taken into account when identifying suitable candidates for inclisiran therapy in clinical settings. They are listed in the Table 2 below [126].

**Table 2.** Considerations for inclisiran prescription [126].

Indications for Initiating Inclisiran	Possible Impediments to Taking Inclisiran
Prior diagnosis of ASCVD or HeFH	Challenges in securing insurance coverage for inclisiran-based therapy
Inability or reluctance to use a self-injectable PCSK9 monoclonal antibody	Limited access to specialized care facilities due to geographical constraints or transportation issues
Need for further reduction in LDL cholesterol despite maximal statin therapy (with or without ezetimibe)	Patients belonging to demographic groups with limited safety data available for inclisiran use, such as those with CHF, liver disease, CKD, or pregnant women
Challenges with adhering to a bi-weekly dosing regimen of PCSK9 monoclonal antibodies; Potential consideration in patients experiencing statin-related side effects or demonstrating poor adherence to therapy, or encountering adverse effects from PCSK9 monoclonal antibodies	High out-of-pocket expenses for specific patients depending on their insurance coverage


ASCVD, atherosclerotic cardiovascular disease; HeFH, heterozygous familial hypercholesterolemia; CHF, congestive heart failure; CKD, chronic kidney disease.

### 3.5. Canakinumab

Canakinumab is a monoclonal antibody which, by its action, neutralizes IL-1 $\beta$  signaling by blocking the inflammatory pathway [127,128]. Canakinumab directly inhibits IL-1 $\beta$ , while indirectly inhibiting matrix metalloproteinase (MMP), VCAM, intercellular adhesion molecule (ICAM), IL-6, and fibrinogen. The antibody has been approved by the FDA for the treatment of a number of conditions, which are shown in the Figure 4 below [129].

IL-1 $\beta$  is one of the first interleukins, which is an important mediator between intercellular communication in the immune system and is an important factor responsible for the immune response in atherosclerosis. IL-1 $\beta$  locally in the vessel wall causes the expression of adhesion molecules, cytokines, and chemokines and enhances the inflammatory response. There is evidence to suggest a proatherogenic effect of IL-1 $\beta$  in vascular smooth muscle through the induction of pro-inflammatory factors. As for its effect on the body, on the other hand, it mainly derives inflammation induced mainly by pro-inflammatory IL-6. Inflammation can be easily and quickly verified by rising blood levels of hsCRP, as its increase is clearly correlated with the pro-inflammatory effects of IL-1 $\beta$  and IL-6 [130]. One small study showed in patients with atherosclerosis and impaired glucose tolerance or type 2 diabetes a reduction in atherosclerotic plaque progression in the carotid arteries, reduced inflammation, and better perfusion of lower extremity musculature [131].

Regarding the effect of canakinumab, the randomized, double-blind, placebo-controlled CANTOS trial has been conducted [130,132,133]. This study included more than 10,000 patients with a history of MI and with hsCRP above 2 mg/L. The subjects were treated with hypolipemic therapy according to current recommendations, i.e., statins, and their cholesterol was 80 mg/dL. Participants received canakinumab—50,150, or 300 mg—or placebo subcutaneously every 3 months for 3.7 years [130,132,134].



**Figure 4.** Indications for the use of Canakinumab [129].

The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) clinical trial looked at whether inhibition of IL-1 $\beta$ -induced inflammation could be effectively used for secondary prevention in high-risk patients in atherosclerotic ischemic incidents [130,134,135].

The study's conclusions were a 15% reduction in the occurrence of three situations: non-fatal MI, fatal stroke, and a reduction in death overall from cardiovascular causes in those taking the 150 mg dose. The higher dose, 300 mg, had virtually the same effect as 150 mg, while the three-times-lower dose non-significantly reduced the situations studied. Thus, the conclusion is that a dose of at least 150 mg is protective against cardiovascular events in secondary prevention and is independent of the reduction in serum lipid levels. The use of canakinumab reduced hsCRP levels and thus generalized inflammation without reducing LDL cholesterol levels [130]. The most important positive results are mainly related to the reduction in the number of MIs, the reduction in the need for coronary revascularization, and the prevention of recurrent ischemic events in patients with both CKD and diabetes [130,132]. As for observed side effects, canakinumab increased the frequency of neutropenia, the risk of infections, and deaths from infections [134]. Above all, due to the anti-inflammatory effect of the drug, the greatest adverse effect was a decrease in the immunity of the recipient, thereby increasing the frequency of the above-mentioned infections [132]. The authors of the CANTOS study also believe that the antibody reduces atherothrombosis and causes many beneficial changes in the late stages of atherosclerosis, such as remodeling and collagen formation, but this still requires more research [136].

### 3.6. Tocilizumab

Tocilizumab is a recombinant humanized monoclonal antibody directed against the IL-6 receptor [137,138]. IL-6 is produced by T and B cells, fibroblasts, and monocytes. It is responsible for various processes such as T-cell activation, hemopoiesis, induction of hepatic acute phase protein synthase, and immunoglobulin secretion [139]. This drug is used in patients with rheumatoid arthritis or COVID-19 [140]. In patients with STEMI-type MI, an improvement in myocardial survival rate was observed after administration within

6 h of the incident IL-6 receptor antagonist. This showed a potential protective effect, but at the same time did not affect the final extent of the infarction. Thus, the study shows for the time being an uncertain effect on the cardiovascular system [141]. In one prospective cohort study, 28 patients with RA were observed. They received tocilizumab subcutaneously at a dose of 162 mg once a week or intravenously at 4 mg/kg b.w. every 4 weeks. After 3 months, the effect on the presence of underlying disease was evaluated, but we will focus on the effect on lipid parameters. The following parameters increased: total cholesterol, LDL-C, non-HDL-C (high-density lipoprotein cholesterol), and apo-B; while Lp(a) and oxLDL decreased. However, no changes were noted in the levels of triglycerides, HDL-C and apo A-I. This study demonstrates the “lipid paradox”, i.e., an increase in lipid parameters with a concomitant decrease in inflammation in the body, which should be looked at in future studies [140]. It is noteworthy that in the CANTOS study mentioned with the previous drug, a reduction in cardiovascular risk was simultaneously associated with a reduction in IL-6 levels [142]. Thus, the possibility of tocilizumab should be looked at in connection with a non-traditional approach to cardiovascular risk factors and focusing on the presence of pro-inflammatory factors [143].

### 3.7. Janus Kinase Inhibitors

The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases, represented by JAK1, JAK2, JAK3, and Tyk2, are responsible for signal transduction from membrane receptors to the cell nucleus via the JAK/STAT pathway, leading to the modulation of cell proliferation, differentiation, and apoptosis [144]. JAK inhibitors such as tofacitinib and baricitinib have found wide application in the treatment of inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and various dermatological conditions [145,146]. In SMC present in blood vessels, JAK/STAT participates in promoting proliferation associated with injury and angiotensin II-induced intracellular signaling. This suggests that JAK plays a significant role in the pathogenesis of numerous vascular diseases such as systemic hypertension, post-angioplasty restenosis, and atherosclerosis [147]. In rodent studies, it has been shown that blocking the activity or expression of JAK3 reduces the proliferation of smooth muscle cells induced by platelet-derived growth factor-BB (PDGF-BB) and inhibits injury-induced intimal hyperplasia [144]. Moreover, JAK3 plays a significant role in modulating the inflammatory response through the regulation of signal transducer and activator of transcription 3 (STAT3) activation, a key mediator of vascular responses to inflammation, and by participating in IL-6-dependent macrophage differentiation and IL-8-induced neutrophil chemotaxis. The recruitment of these cells to the injured blood vessel strongly correlates with subsequent neointimal formation [148–150]. The significant involvement of JAK in vascular remodeling processes suggests that JAK inhibitors may be utilized in the future as therapeutics for preventing the development of atherosclerosis and other vascular diseases. However, further research in this domain is necessary at present.

### 3.8. SGLT2 Inhibitors

The sodium-glucose cotransporter 2 (SGLT2) is the primary transporter of glucose located in the renal proximal tubule, responsible for transporting glucose from the renal tubule lumen into renal tubule epithelial cells [151]. The mechanism of action of SGLT2 inhibitors (SGLT2i) is based on inhibiting this protein, leading to a decrease in glucose concentration in the serum [151]. In addition to their main function, drugs from this group contribute to delaying the process of atherosclerosis by improving endothelial and VSMC dysfunction, preventing platelet activation, attenuating oxidative stress, and reducing inflammation [152]. Furthermore, SGLT2 inhibitors demonstrate a varied impact on metabolism, indirectly contributing to the slowing down of atherosclerosis processes. Meta-analyses of clinical trials conducted on patients treated with SGLT2i have indicated significant weight loss among the studied subjects, primarily attributed to calorie loss and the conversion of glucose metabolism to ketones and fatty acids. This process enhances

fat utilization, ultimately resulting in weight reduction [153,154]. Additionally, SGLT2i reduce serum uric acid levels, which is hypothesized to act as a promoter of inflammatory processes and oxidative stress [155,156]. Another mechanism through which SGLT2i counteracts atherosclerosis is their influence on macrophages. Autophagy contributes to the removal of apoptotic macrophages from atherosclerotic plaques. Inhibiting autophagy renders macrophages more susceptible to cell death, exacerbating necrosis in advanced stages of atherosclerosis [157]. Studies conducted on mice have shown that canagliflozin could delay the progression of atherosclerosis by promoting macrophage autophagy. Canagliflozin promotes the expression of LC3II and the formation of autophagosomes, as well as enhancing cholesterol efflux from macrophages, resulting in lower lipid droplet concentrations in macrophages [158].

### 3.9. RAAS Inhibitors

Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEI) are widely used medications whose main function is to inhibit the renin-angiotensin-aldosterone system (RAAS). The RAAS is a system that plays an important role in maintaining the body's electrolyte and fluid balance. However, it is a system closely associated with NADPH oxidase, which is an enzyme contributing to the generation of reactive oxygen species (ROS), the excessive production of which contributes to vascular injury and promotes atherogenesis. Additionally, the final effector of the RAAS, angiotensin II, is responsible for promoting inflammation, fibrosis, and acting directly on blood vessels to cause vasoconstriction [159]. These factors suggest that chronic activation of the RAAS may promote atherosclerosis and therapy with drugs inhibiting this system may lead to slowing down of atherosclerosis. Additionally, ARBs exhibit a broad spectrum of beneficial effects on vascular metabolism, including anti-inflammatory and antioxidative actions, which play a significant role in cardiovascular protection. Chronic therapy with ARBs reduces the onset of CVDs and decreases the likelihood of serious complications associated with these diseases, which is attributed to the hypotensive properties of these drugs [160].

### 3.10. GLP-1RA

GLP-1 receptor agonists (GLP-1RA) are new medications used in the treatment of type 2 diabetes. The mechanism of action of these drugs involves binding to the GLP-1 receptor (GLP-1R) and exerting incretin effects, which include glucose-dependent insulin secretion from pancreatic beta cells, inhibition of glucagon secretion from pancreatic alpha cells, and slowing of gastric emptying. GLP-1RA also acts centrally on neurons in the hypothalamus, inducing a feeling of satiety. Therapy with GLP-1RA reduces appetite, leading to weight loss, which indirectly contributes to their antiatherosclerotic effects [161]. GLP-1RA leads to a decrease in macrophage and monocyte accumulation in the arterial wall by inhibiting the inflammatory response in macrophages [162]. In studies conducted on mice, it was demonstrated that therapy with lixisenatide and liraglutide contributed to a significant reduction in the size of atheroma plaques [163]. Additionally, it has been demonstrated that GLP-1RA lead to a decrease in the level of CRP and pro-inflammatory cytokines and an increase in the level of adiponectin, which acts as an anti-inflammatory agent [164,165]. The anti-inflammatory action exerted by GLP-1RA indirectly affects the slowing of processes related to atherogenesis.

### 3.11. Antiplatelet Drugs

Platelets significantly contribute to the progression of atherosclerosis due to their interactions with endothelial cells of blood vessels and the release of inflammatory mediators, which initiate atherogenesis [166]. Antiplatelet drugs, through their anti-inflammatory effects and inhibitory influence on platelets, not only prevent thromboembolic events underlying the pathogenesis of ACS but may also exert a positive impact on slowing down processes associated with atherogenesis. Acetylsalicylic acid (ASA) acts by inhibiting cyclooxygenase-1 (COX-1), reducing the production of thromboxane A<sub>2</sub> (TXA<sub>2</sub>), a

vasoconstrictor that stimulates platelet aggregation [167]. Inhibiting COX-1 contributes to preventing cyclooxygenase-mediated cell proliferation and reducing the concentration of pro-inflammatory cytokines [168]. ASA also affects the reduction of IL release from platelets and is associated with the inhibition of endothelial dysfunction linked to the inflammatory process [169]. Moreover, ASA exhibits antioxidative properties and increases the availability of nitric oxide (NO), a natural vasodilator [170]. It has been demonstrated that ASA at a daily dose of 300 mg is associated with a significant reduction in the concentration of inflammatory markers such as IL-6 and CRP [168].

Cilostazol is an antiplatelet agent, acting through the inhibition of phosphodiesterase-3 (PDE-3) and subsequent elevation of cyclic adenosine monophosphate (cAMP) levels [171]. Its primary function is the inhibition of platelet aggregation, yet it also demonstrates anti-inflammatory, vasodilatory, and antioxidative properties, and improves lipid profile [172]. Administration of cilostazol leads to the phosphorylation of protein kinase A (PKA), resulting in the activation of endothelial nitric oxide synthase (eNOS), thereby increasing NO levels [173]. Elevated cAMP levels also contribute to the increased NO secretion by vascular endothelial cells, which is cAMP-dependent. Moreover, the increase in cAMP levels induces vessel dilation by stimulating the PKA-dependent activation of calcium-dependent potassium channels [174]. Moreover, cilostazol improves the lipid profile by upregulating lipoprotein lipase in adipose tissue and inhibiting PDE-3 in adipocytes [175,176]. Animal studies have demonstrated that cilostazol administration stimulates the expression of LDL receptor-related protein 1 (LRP1) in hepatocytes, which may significantly impact triglycerides and HDL-C improvement [177].

### 3.12. Sex Differences

Sex-related disparities in the efficacy and safety profiles of drugs with anti-inflammatory effects are increasingly recognized in the context of limiting the progression of ASCVD. Studies have indicated that canakinumab has shown promising results in reducing cardiovascular events and inflammation [178]. Additionally, statins, a cornerstone in ASCVD management, may exhibit differential effectiveness and adverse event rates between men and women, possibly influenced by variations in drug metabolism and hormone levels [179]. Estrogen, predominant in females, has been associated with potential cardioprotective effects, including anti-inflammatory properties and modulation of lipid metabolism, which might enhance the response to statins in women [180]. Conversely, androgens, more prevalent in males, might influence the metabolism and efficacy of certain anti-inflammatory medications. PCSK9 inhibitors have shown promising results in reducing cardiovascular events, yet emerging evidence suggests potential sex-specific responses to these agents, warranting further investigation [181]. Bempedoic acid, a novel cholesterol-lowering therapy, has demonstrated efficacy in both sexes; however, sex-based differences in tolerability and long-term cardiovascular outcomes require elucidation [122]. Similarly, newer agents like inclisiran, an RNA-targeted therapy, may exhibit sex-specific responses influencing their therapeutic benefits [182]. Moreover, while SGLT2 inhibitors and GLP-1 receptor agonists have shown cardiovascular benefits across sexes, the mechanisms underlying these effects and potential sex-related differences merit exploration [183]. Furthermore, antiplatelet drugs and RAAS inhibitors have well-established roles in ASCVD management, yet their efficacy and safety profiles may vary between men and women due to physiological and hormonal disparities. Understanding these sex-related differences in drug responses is crucial for optimizing treatment strategies and improving cardiovascular outcomes in both men and women [184].

### 3.13. Smoking Cessation

It is widely known that tobacco smoking is one of the most significant risk factors for cardiovascular events. The main mechanisms through which smoking contributes to the initiation of atherogenesis include endothelial dysfunction, induction of inflammation, elevation of pro-atherogenic lipid levels, and reduction in HDL levels [185]. Despite the

widespread awareness of the harmful effects of smoking, patients often significantly struggle to quit smoking due to the highly addictive nature of nicotine. During the smoking cessation process, individuals may experience physical withdrawal symptoms such as difficulty concentrating, increased appetite, insomnia, restlessness, and anxiety [186,187]. To reduce withdrawal symptoms and thereby increase the likelihood of maintaining abstinence, pharmacological treatment can support patients. In recent years, substantial evidence has emerged, demonstrating the effectiveness of medications such as varenicline, cytisine, or antidepressant medications, among which bupropion exhibits the greatest efficacy in aiding smoking cessation [188–190]. Despite its effectiveness in alleviating nicotine withdrawal symptoms, varenicline exhibits adverse effects. In 2011, the FDA advised that varenicline may slightly increase the risk of cardiovascular events among patients with CVDs [189].

### 3.14. Proper Diet

The most desirable and least costly method to reduce cardiovascular risk is primary prevention, understood as primarily addressing obesity [191]. We have evidence that diet can affect the development of atherosclerosis [192]. Weight reduction affects lipidogram, systemic inflammation, and glucose metabolism, including a reduction in fasting glucose, hemoglobin A1c (HbA1c), and blood pressure, as well as disease progression [191,193]. Weight reduction through a calorie-restricted diet, in addition to weight change, improves insulin resistance, delays aging, or extends life expectancy [191]. A diet with reduced caloric intake improves atherosclerotic markers, reduces inflammatory markers such as hsCRP, nuclear factor kappa B, NFB, TNF $\alpha$ , and reduces superoxide production [193]. We know the factors that negatively affect the risk of cardiovascular factors, that is, poor hygiene and amount of sleep, poor diet, stress, little exercise, and poor air [191].

Lifestyle changes resulting in the reduction of risk factors should be implemented in patients' lives through self-education or by preventive health practitioners to reduce the progression of atherosclerosis [194]. A proper dietary pattern is the main primary prevention of ASCVD [186]. The Table 3 shows the elements of a proper dietary pattern that will reduce the risk of ASCVD and the elements that will act adversely [195,196].

**Table 3.** Food items that increase and decrease the risk of AVSCD [195,196].

Products That Decrease Risk of ASCVD	Products That Increase Risk of ASCVD
Fruits and non-starchy vegetables	Red and processed meats
Nuts	Refined carbohydrates
Legumes	Salt
Fish	Saturated fats
Vegetable oils	Added sugars
Whole grains	Ultra-processed foods

ASCVD—atherosclerotic cardiovascular disease.

Due to the importance of diet in our lives, it is important to create good eating habits from the beginning in order to prevent inflammation in the body so that we can confidently inhibit the development of atherosclerosis [197].

## 4. Conclusions

Atherosclerosis is a typical vascular aging disease. Nonetheless, a number of variables might influence this process, increasing cardiovascular risk and resulting in a high rate of morbidity and death. In this review, we concentrated on the key molecular features of arteriosclerosis. We focused on the immune system's involvement, dysfunctions, and impact on the progression of this disease. In light of atherosclerosis affecting over 230 million people globally, identifying biomarkers is essential for assessing risk and monitoring disease progression. Research has identified key biomarkers related to inflammation, such as the inflammasome, GDF-15, and immune cells impacting ox-LDL serum levels, particularly relevant in younger CAD patients for prognostic insights. Additionally, FGF-23 is elevated

in a population with an increased risk of atherosclerotic lesions. Exosomes role in the development of CVDs were all regarded important. Exosomes—extracellular vesicles rich in miRNAs, lncRNAs, circRNAs—emerge as pivotal in understanding atherosclerosis due to their roles in cellular communication and disease mechanics. These findings underline the potential of exosomal miRNAs and non-coding RNAs as promising biomarkers for advancing the diagnosis, prognosis, and therapeutic targeting of atherosclerosis, highlighting the need for further research to integrate these biomarkers into clinical practice. Furthermore, because of the increasing number of people suffering for atherosclerotic CVD, we presented both well-known medicaments and newly discovered examples such as inclisiran, canakinumab, and Janus kinase inhibitors.

**Author Contributions:** Conceptualization, B.F., E.M. and J.R.; methodology, P.F., W.C., B.D., W.L., E.R., A.W. and E.M.; software, E.M.; validation, B.F., E.M. and J.R.; formal analysis, P.F., W.C., B.D., W.L., E.R. and A.W.; investigation, P.F., W.C., B.D., W.L., E.R. and A.W.; resources, B.F., E.M. and J.R.; data curation, E.M.; writing—original draft preparation, P.F., W.C., B.D., W.L., E.R., A.W. and E.M.; writing—review and editing, E.M.; visualization, P.F., W.C., B.D., W.L., E.R., A.W. and E.M.; supervision, B.F., E.M. and J.R.; project administration, B.F., E.M. and J.R.; funding acquisition, B.F. and J.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data used in this article were sourced from materials mentioned in the References section.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

- Sandesara, P.B.; Virani, S.S.; Fazio, S.; Shapiro, M.D. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. *Endocr Rev.* **2019**, *40*, 537–557. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Libby, P.; Buring, J.E.; Badimon, L.; Hansson, G.K.; Deanfield, J.; Bittencourt, M.S.; Tokgözoğlu, L.; Lewis, E.F. Atherosclerosis. *Nat. Rev. Dis. Primers* **2019**, *5*, 56. [[CrossRef](#)] [[PubMed](#)]
- Gui, Y.; Zheng, H.; Cao, R.Y. Foam Cells in *Atherosclerosis*: Novel Insights into Its Origins, Consequences, and Molecular Mechanisms. *Front. Cardiovasc. Med.* **2022**, *9*, 845942. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Björkegren, J.L.M.; Lusis, A.J. *Atherosclerosis*: Recent developments. *Cell* **2022**, *185*, 1630–1645. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Khatana, C.; Saini, N.K.; Chakrabarti, S.; Saini, V.; Sharma, A.; Saini, R.V.; Saini, A.K. Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced *Atherosclerosis*. *Oxid. Med. Cell Longev.* **2020**, *2020*, 5245308. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Kou, H.; Wang, H.; Liu, P.; Wang, X.; Zhu, W.; Jiang, W.; Hu, X.; Deng, J. Prevalence, clinical features and prognosis of familial hypercholesterolemia in Chinese Han patients with acute coronary syndrome after a coronary event: A retrospective observational study. *BMC Cardiovasc. Disord.* **2024**, *24*, 144. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Otsuka, K.; Yamaura, H.; Shimada, K.; Sugiyama, T.; Hojo, K.; Ishikawa, H.; Kono, Y.; Kasayuki, N.; Fukuda, D. Impact of diabetes mellitus and triglyceride glucose index on mortality and cardiovascular outcomes in patients with chronic coronary syndrome undergoing coronary computed tomography angiography. *Int. J. Cardiol. Cardiovasc. Risk. Prev.* **2024**, *20*, 200250. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Shen, S.; Zhong, H.; Zhou, X.; Li, G.; Zhang, C.; Zhu, Y.; Yang, Y. Advances in Traditional Chinese Medicine research in diabetic kidney disease treatment. *Pharm. Biol.* **2024**, *62*, 222–232. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Düsing, P.; Zietzer, A.; Goody, P.R.; Hosen, M.R.; Kurts, C.; Nickenig, G.; Jansen, F. Vascular pathologies in chronic kidney disease: Pathophysiological mechanisms and novel therapeutic approaches. *J. Mol. Med.* **2021**, *99*, 335–348. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Bäck, M.; Yurdagul, A., Jr.; Tabas, I.; Öörni, K.; Kovanen, P.T. Inflammation and its resolution in atherosclerosis: Mediators and therapeutic opportunities. *Nat. Rev. Cardiol.* **2019**, *16*, 389–406. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Muñoz-Barrera, L.; Perez-Sanchez, C.; Ortega-Castro, R.; Corrales, S.; Luque-Tevar, M.; Cerdó, T.; Sanchez-Pareja, I.; Font, P.; Lopez-Mejias, R.; Calvo, J.; et al. Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs. *Biomed. Pharmacother.* **2024**, *173*, 116357. [[CrossRef](#)] [[PubMed](#)]

12. Bailey, A.L.; Al-Adwan, S.; Sneij, E.; Campbell, N.; Wiisanen, M.E. Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection. *Curr. Cardiol. Rep.* **2021**, *23*, 52. [[CrossRef](#)] [[PubMed](#)]
13. Bułdak, Ł. Cardiovascular Diseases—A Focus on *Atherosclerosis*, Its Prophylaxis, Complications and Recent Advancements in Therapies. *Int. J. Mol. Sci.* **2022**, *23*, 4695. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
14. Toraldo, D.M.; Piscitelli, P.; De Nuccio, F. Obstructive Sleep Apnoea (OSA) and early atherosclerosis: The role of microbiota and EVs. *Pulmonology* **2024**. [[CrossRef](#)] [[PubMed](#)]
15. Lechner, K.; von Schacky, C.; McKenzie, A.L.; Worm, N.; Nixdorff, U.; Lechner, B.; Kränkel, N.; Halle, M.; Krauss, R.M.; Scherr, J. Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors. *Eur. J. Prev. Cardiol.* **2020**, *27*, 394–406. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
16. Reynolds, H.R.; Cyr, D.D.; Merz, C.N.B.; Shaw, L.J.; Chaitman, B.R.; Boden, W.E.; Alexander, K.P.; Rosenberg, Y.D.; Bangalore, S.; Stone, G.W.; et al. ISCHEMIA Research Group \*. Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients with Chronic Coronary Disease: Insights From the ISCHEMIA Trial. *J. Am. Heart Assoc.* **2024**, *13*, e029850. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
17. Apte, R.S.; Chen, D.S.; Ferrara, N. VEGF in Signaling and Disease: Beyond Discovery and Development. *Cell* **2019**, *176*, 1248–1264. [[CrossRef](#)]
18. Takenoshita, Y.; Tokito, A.; Jougasaki, M. Inhibitory Effects of Eicosapentaenoic Acid on Vascular Endothelial Growth Factor-Induced Monocyte Chemoattractant Protein-1, Interleukin-6, and Interleukin-8 in Human Vascular Endothelial Cells. *Int. J. Mol. Sci.* **2024**, *25*, 2749. [[CrossRef](#)]
19. Pedro-Botet, J.; Climent, E.; Benaiges, D. *Atherosclerosis* and inflammation. New therapeutic approaches. *Med. Clin.* **2020**, *155*, 256–262. [[CrossRef](#)] [[PubMed](#)]
20. Nordestgaard, B.G.; Zacho, J. Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander? *Nutr. Metab. Cardiovasc. Dis.* **2009**, *19*, 521–524. [[CrossRef](#)] [[PubMed](#)]
21. Denegri, A.; Boriani, G. High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. *Curr. Pharm. Des.* **2021**, *27*, 263–275. [[CrossRef](#)] [[PubMed](#)]
22. Krishnan, S.M.; Dowling, J.K.; Ling, Y.H.; Diep, H.; Chan, C.T.; Ferens, D.; Kett, M.M.; Pinar, A.; Samuel, C.S.; Vinh, A.; et al. Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice. *Br. J. Pharmacol.* **2016**, *173*, 752–765. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
23. Caocci, M.; Niu, M.; Fox, H.S.; Burdo, T.H. HIV Infection Drives Foam Cell Formation via NLRP3 Inflammasome Activation. *Int. J. Mol. Sci.* **2024**, *25*, 2367. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
24. Sharma, B.R.; Kanneganti, T.D. NLRP3 inflammasome in cancer and metabolic diseases. *Nat. Immunol.* **2021**, *22*, 550–559. [[CrossRef](#)] [[PubMed](#)]
25. Malech, H.L.; DeLeo, F.R.; Quinn, M.T. The Role of Neutrophils in the Immune System: An Overview. *Methods Mol. Biol.* **2020**, *2087*, 3–10. [[CrossRef](#)] [[PubMed](#)]
26. Hu, Z.; Murakami, T.; Tamura, H.; Reich, J.; Kuwahara-Arai, K.; Iba, T.; Tabe, Y.; Nagaoka, I. Neutrophil extracellular traps induce IL-1beta production by macrophages in combination with lipopolysaccharide. *Int. J. Mol. Med.* **2017**, *39*, 549–558. [[CrossRef](#)] [[PubMed](#)]
27. Choy, E.H.; De Benedetti, F.; Takeuchi, T.; Hashizume, M.; John, M.R.; Kishimoto, T. Translating IL-6 biology into effective treatments. *Nat. Rev. Rheumatol.* **2020**, *16*, 335–345. [[CrossRef](#)]
28. Gorreja, F.; Bendix, M.; Rush, S.T.A.; Maasfeh, L.; Savolainen, O.; Dige, A.; Agnholt, J.; Öhman, L.; Magnusson, M.K. Fecal Supernatants from Patients with Crohn’s Disease Induce Inflammatory Alterations in M2 Macrophages and Fibroblasts. *Cells* **2023**, *13*, 60. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
29. Makris, A.; Barkas, F.; Sfrikakis, P.P.; Liberopoulos, E.; Filippatos, T.D.; Ray, K.K.; Agouridis, A.P. Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association? *Atheroscler. Plus* **2023**, *54*, 1–6. [[CrossRef](#)] [[PubMed](#)]
30. Ridker, P.M.; Devalaraja, M.; Baeres, F.M.M.; Engelmann, M.D.; Hovingh, G.K.; Ivkovic, M.; Lo, L.; Kling, D.; Pergola, P.; Raj, D.; et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet* **2021**, *397*, 2060–2069. [[CrossRef](#)]
31. Marchio, P.; Guerra-Ojeda, S.; Vila, J.M.; Aldasoro, M.; Victor, V.M.; Mauricio, M.D. Targeting Early *Atherosclerosis*: A Focus on Oxidative Stress and Inflammation. *Oxid. Med. Cell Longev.* **2019**, *2019*, 8563845. [[CrossRef](#)] [[PubMed](#)]
32. Pedde, M.; Larson, T.V.; D’Souza, J.; Szpiro, A.A.; Kloog, I.; Lisabeth, L.D.; Jacobs, D.; Sheppard, L.; Allison, M.; Kaufman, J.D.; et al. Coarse Particulate Matter and Markers of Inflammation and Coagulation in the Multi-Ethnic Study of *Atherosclerosis* (MESA) Population: A Repeat Measures Analysis. *Environ. Health Perspect.* **2024**, *132*, 27009. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
33. Gimbrone, M.A., Jr.; García-Cardeña, G. Endothelial Cell Dysfunction and the Pathobiology of *Atherosclerosis*. *Circ. Res.* **2016**, *118*, 620–636. [[CrossRef](#)] [[PubMed](#)]
34. Hadi, H.A.R.; Carr, C.S.; Al Suwaidi, J. Endothelial dysfunction: Cardiovascular risk factors, therapy, and outcome. *Vasc. Health Risk Manag.* **2005**, *1*, 183–198.
35. Jia, C.; Wu, W.; Lu, H.; Liu, J.; Chen, S.; Liang, G.; Zhou, Y.; Yu, S.; Qiao, L.; Chen, J.; et al. Fibrinogen to HDL-Cholesterol ratio as a predictor of mortality risk in patients with acute myocardial infarction. *Lipids Health Dis.* **2024**, *23*, 86. [[CrossRef](#)] [[PubMed](#)]

36. Stec, J.J.; Silbershatz, H.; Tofler, G.H.; Matheney, T.H.; Sutherland, P.; Lipinska, I.; Massaro, J.M.; Wilson, P.F.; Muller, J.E.; D'Agostino, R.B.S. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. *Circulation* **2000**, *102*, 1634–1638. [[CrossRef](#)] [[PubMed](#)]
37. Biscetti, F.; Rando, M.M.; Cecchini, A.L.; Nicolazzi, M.A.; Rossini, E.; Angelini, F.; Iezzi, R.; Eraso, L.H.; Dimuzio, P.J.; Pitocco, D.; et al. The role of Klotho and FGF23 in cardiovascular outcomes of diabetic patients with chronic limb threatening ischemia: A prospective study. *Sci. Rep.* **2023**, *13*, 6150. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
38. Kuro, O.M.; Wahl, P. FGF23 in chronic kidney disease. In *Endocrine FGFs and Klothos*; Kuro, O.M., Ed.; Landes Bioscience and Springer Science: Berlin/Heidelberg, Germany, 2012; pp. 107–125.
39. Kendrick, J.; Cheung, A.K.; Kaufman, J.S.; Greene, T.; Roberts, W.L.; Smits, G.; Chonchol, M. HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. *J. Am. Soc. Nephrol.* **2011**, *22*, 1913–1922. [[CrossRef](#)] [[PubMed](#)]
40. Bennett, D.A.; Holmes, M.V. Mendelian randomisation in cardiovascular research: An introduction for clinicians. *Heart* **2017**, *103*, 1400–1407. [[CrossRef](#)]
41. Nyárady, B.B.; Kiss, L.Z.; Bagyura, Z.; Merkely, B.; Dósa, E.; Láng, O.; Kóhidai, L.; Pállinger, É. Growth and differentiation factor-15: A link between inflammaging and cardiovascular disease. *Biomed. Pharmacother.* **2024**, *174*, 116475. [[CrossRef](#)] [[PubMed](#)]
42. Huang, H.; Chen, Z.; Li, Y.; Gong, K.; Xiao, L.; Fu, H.; Yang, J.; Wang, X.; Meng, Q. GDF-15 Suppresses Atherosclerosis by Inhibiting oxLDL-Induced Lipid Accumulation and Inflammation in Macrophages. *Evid. Based Complement. Altern. Med.* **2021**, *2021*, 6497568. [[CrossRef](#)] [[PubMed](#)]
43. Johnstone, R.M.; Adam, M.; Hammond, J.R.; Orr, L.; Turbide, C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J. Biol. Chem.* **1987**, *262*, 9412–9420. [[CrossRef](#)] [[PubMed](#)]
44. Patel, N.; Chin, D.D.; Chung, E.J. Exosomes in Atherosclerosis, a Double-Edged Sword: Their Role in Disease Pathogenesis and Their Potential as Novel Therapeutics. *AAPS J.* **2021**, *23*, 95. [[CrossRef](#)] [[PubMed](#)]
45. Gurung, S.; Perocheau, D.; Touramanidou, L.; Baruteau, J. The exosome journey: From biogenesis to uptake and intracellular signalling. *Cell Commun. Signal.* **2021**, *19*, 47. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
46. Yu, X.; Odenthal, M.; Fries, J.W. Exosomes as miRNA Carriers: Formation-Function-Future. *Int. J. Mol. Sci.* **2016**, *17*, 2028. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
47. Li, Z.; Meng, X.; Wu, P.; Zha, C.; Han, B.; Li, L.; Sun, N.; Qi, T.; Qin, J.; Zhang, Y.; et al. Glioblastoma Cell-Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance. *Cancer Immunol. Res.* **2021**, *9*, 1383–1399. [[CrossRef](#)] [[PubMed](#)]
48. Kong, L.; Zhu, L.; Yi, X.; Huang, Y.; Zhao, H.; Chen, Y.; Yuan, Z.; Wen, L.; Wu, J.; Yi, J. Betulinic Acid Alleviates Spleen Oxidative Damage Induced by Acute Intraperitoneal Exposure to T-2 Toxin by Activating Nrf2 and Inhibiting MAPK Signaling Pathways. *Antioxidants* **2021**, *10*, 158. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
49. Jansen, F.; Yang, X.; Proebsting, S.; Hoelscher, M.; Przybilla, D.; Baumann, K.; Schmitz, T.; Dolf, A.; Endl, E.; Franklin, B.S.; et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. *J. Am. Heart Assoc.* **2014**, *3*, e001249. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
50. Jiang, H.; Toscano, J.F.; Song, S.S.; Schlick, K.H.; Dumitrascu, O.M.; Pan, J.; Lyden, P.D.; Saver, J.L.; Gonzalez, N.R. Differential expression of circulating exosomal microRNAs in refractory intracranial atherosclerosis associated with antiangiogenesis. *Sci. Rep.* **2019**, *9*, 19429, Erratum in *Sci. Rep.* **2021**, *11*, 15266. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
51. Liu, Y.; Li, Q.; Hosen, M.R.; Zietzer, A.; Flender, A.; Levermann, P.; Schmitz, T.; Frühwald, D.; Goody, P.; Nickenig, G.; et al. Atherosclerotic Conditions Promote the Packaging of Functional MicroRNA-92a-3p Into Endothelial Microvesicles. *Circ. Res.* **2019**, *124*, 575–587. [[CrossRef](#)] [[PubMed](#)]
52. Wang, Z.; Zhang, J.; Zhang, S.; Yan, S.; Wang, Z.; Wang, C.; Zhang, X. MiR-30e and miR-92a are related to atherosclerosis by targeting ABCA1. *Mol. Med. Rep.* **2019**, *19*, 3298–3304. [[CrossRef](#)] [[PubMed](#)]
53. Haemmig, S.; Simion, V.; Feinberg, M.W. Long Non-Coding RNAs in Vascular Inflammation. *Front. Cardiovasc. Med.* **2018**, *5*, 22. [[CrossRef](#)] [[PubMed](#)]
54. Simion, V.; Zhou, H.; Haemmig, S.; Pierce, J.B.; Mendes, S.; Tesmenitsky, Y.; Pérez-Cremades, D.; Lee, J.F.; Chen, A.F.; Ronda, N.; et al. A macrophage-specific lncRNA regulates apoptosis and atherosclerosis by tethering HuR in the nucleus. *Nat. Commun.* **2020**, *11*, 6135. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
55. Hu, Y.W.; Guo, F.X.; Xu, Y.J.; Li, P.; Lu, Z.F.; McVey, D.G.; Zheng, L.; Wang, Q.; Ye, J.H.; Kang, C.M.; et al. Long noncoding RNA NEXN-AS1 mitigates atherosclerosis by regulating the actin-binding protein NEXN. *J. Clin. Investig.* **2019**, *129*, 1115–1128. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
56. Khyzha, N.; Khor, M.; DiStefano, P.V.; Wang, L.; Matic, L.; Hedin, U.; Wilson, M.D.; Maegdefessel, L.; Fish, J.E. Regulation of CCL2 expression in human vascular endothelial cells by a neighboring divergently transcribed long noncoding RNA. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 16410–16419. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
57. Li, X.; Yang, L.; Chen, L.L. The Biogenesis, Functions, and Challenges of Circular RNAs. *Mol. Cell* **2018**, *71*, 428–442. [[CrossRef](#)] [[PubMed](#)]
58. Zhuang, J.B.; Li, T.; Hu, X.M.; Ning, M.; Gao, W.Q.; Lang, Y.H.; Zheng, W.F.; Wei, J. Circ\_CHFR expedites cell growth, migration and inflammation in ox-LDL-treated human vascular smooth muscle cells via the miR-214-3p/Wnt3/ $\beta$ -catenin pathway. *Eur. Rev. Med. Pharmacol. Sci.* **2020**, *24*, 3282–3292. [[CrossRef](#)] [[PubMed](#)]

59. Wu, S.; Yang, S.; Qu, H. Circ\_CHFR regulates ox-LDL-mediated cell proliferation, apoptosis, and EndoMT by miR-15a-5p/EGFR axis in human brain microvessel endothelial cells. *Open Life Sci.* **2021**, *16*, 1053–1063. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
60. Li, Y.; Wang, B. Circular RNA circCHFR downregulation protects against oxidized low-density lipoprotein-induced endothelial injury via regulation of microRNA-15b-5p/growth arrest and DNA damage inducible gamma. *Bioengineered* **2022**, *13*, 4481–4492. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
61. Lu, Q.; Li, Y.; Lou, J.; Li, P.; Gu, Y.; Wang, X. Circ-CHFR modulates the proliferation, migration, and invasion of ox-LDL-induced human aorta vascular smooth muscle cells through the miR-214-3p/PAPPA axis. *Clin. Hemorheol. Microcirc.* **2022**, *80*, 399–412. [[CrossRef](#)] [[PubMed](#)]
62. Wang, M.; Li, C.; Cai, T.; Zhang, A.; Cao, J.; Xin, H. Circ\_CHFR Promotes Platelet-Derived Growth Factor-BB-Induced Proliferation, Invasion, and Migration in Vascular Smooth Muscle Cells via the miR-149-5p/NRP2 Axis. *J. Cardiovasc. Pharmacol.* **2022**, *79*, e94–e102. [[CrossRef](#)] [[PubMed](#)]
63. Reustle, A.; Torzewski, M. Role of p38 MAPK in Atherosclerosis and Aortic Valve Sclerosis. *Int. J. Mol. Sci.* **2018**, *19*, 3761. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
64. Hartley, A.; Haskard, D.; Khamis, R. Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis—Novel insights and future directions in diagnosis and therapy. *Trends Cardiovasc. Med.* **2019**, *29*, 22–26. [[CrossRef](#)] [[PubMed](#)]
65. Huang, Y.; Hu, Y.; Mai, W.; Cai, X.; Song, Y.; Wu, Y.; Dong, Y.; Huang, H.; He, Z.; Li, W.; et al. Plasma oxidized low-density lipoprotein is an independent risk factor in young patients with coronary artery disease. *Dis. Markers* **2011**, *31*, 295–301. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
66. Bloomer, R.J. Decreased blood antioxidant capacity and increased lipid peroxidation in young cigarette smokers compared to nonsmokers: Impact of dietary intake. *Nutr. J.* **2007**, *6*, 39. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
67. Stary, H.C.; Chandler, A.B.; Dinsmore, R.E.; Fuster, V.; Glagov, S.; Insull, W., Jr.; Rosenfeld, M.E.; Schwartz, C.J.; Wagner, W.D.; Wissler, R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* **1995**, *92*, 1355–1374. [[CrossRef](#)] [[PubMed](#)]
68. Mazzone, A.; Epistolato, M.C.; De Caterina, R.; Storti, S.; Vittorini, S.; Sbrana, S.; Gianetti, J.; Bevilacqua, S.; Glauber, M.; Biagini, A.; et al. Neovascularization, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. *J. Am. Coll. Cardiol.* **2004**, *43*, 1670–1676. [[CrossRef](#)] [[PubMed](#)]
69. Schäfer, S.; Zerneck, A. CD8<sup>+</sup> T Cells in Atherosclerosis. *Cells* **2020**, *10*, 37. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
70. Marchini, T.; Hansen, S.; Wolf, D. ApoB-Specific CD4<sup>+</sup> T Cells in Mouse and Human Atherosclerosis. *Cells* **2021**, *10*, 446. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
71. Saigusa, R.; Winkels, H.; Ley, K. T cell subsets and functions in atherosclerosis. *Nat. Rev. Cardiol.* **2020**, *17*, 387–401. [[CrossRef](#)] [[PubMed](#)]
72. Liu, F.; Huang, Y.; Liu, F.; Wang, H. Identification of immune-related genes in diagnosing atherosclerosis with rheumatoid arthritis through bioinformatics analysis and machine learning. *Front. Immunol.* **2023**, *14*, 1126647. [[CrossRef](#)]
73. Chen, J.; Xiang, X.; Nie, L.; Guo, X.; Zhang, F.; Wen, C.; Xia, Y.; Mao, L. The emerging role of Th1 Cells in atherosclerosis and its implications for therapy. *Front. Immunol.* **2023**, *13*, 1079668. [[CrossRef](#)]
74. Butcher, M.J.; Gjurich, B.N.; Phillips, T.; Galkina, E.V. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. *Circ. Res.* **2012**, *110*, 675–687. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
75. Kyaw, T.; Winship, A.; Tay, C.; Kanellakis, P.; Hosseini, H.; Cao, A.; Li, P.; Tipping, P.; Bobik, A.; Toh, B.-H. Cytotoxic and Proinflammatory CD8<sup>+</sup> T Lymphocytes Promote Development of Vulnerable Atherosclerotic Plaques in ApoE-Deficient Mice. *Circulation* **2013**, *127*, 1028–1039. [[CrossRef](#)] [[PubMed](#)]
76. Cohen, N.R.; Garg, S.; Brenner, M.B. Antigen Presentation by CD1 Lipids, T Cells, and NKT Cells in Microbial Immunity. *Adv. Immunol.* **2009**, *102*, 1–94. [[CrossRef](#)] [[PubMed](#)]
77. Kyriakakis, E.; Cavallari, M.; Andert, J.; Philippova, M.; Koella, C.; Bochkov, V.; Erne, P.; Wilson, S.B.; Mori, L.; Biedermann, B.C.; et al. Invariant natural killer T cells: Linking inflammation and neovascularization in human atherosclerosis. *Eur. J. Immunol.* **2010**, *40*, 3268–3279. [[CrossRef](#)] [[PubMed](#)]
78. Boivin, W.A.; Cooper, D.M.; Hiebert, P.R.; Granville, D.J. Intracellular versus extracellular granzyme B in immunity and disease: Challenging the dogma. *Lab. Invest.* **2009**, *89*, 1195–1220. [[CrossRef](#)]
79. Tupin, E.; Nicoletti, A.; Elhage, R.; Rudling, M.; Ljunggren, H.-G.; Hansson, G.K.; Berne, G.P. CD1d-dependent Activation of NKT Cells Aggravates Atherosclerosis. *J. Exp. Med.* **2004**, *199*, 417–422. [[CrossRef](#)]
80. Bonaccorsi, I.; De Pasquale, C.; Campana, S.; Barberi, C.; Cavaliere, R.; Benedetto, F.; Ferlazzo, G. Natural killer Cells in the innate immunity network of atherosclerosis. *Immunol. Lett.* **2015**, *168*, 51–57. [[CrossRef](#)] [[PubMed](#)]
81. Masana, L.; Plana, N.; Andreychuk, N.; Ibarretxe, D. Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. *Pharmacol. Res.* **2023**, *190*, 106738. [[CrossRef](#)] [[PubMed](#)]
82. Sirtori, C.R. The pharmacology of statins. *Pharmacol. Res.* **2014**, *88*, 3–11. [[CrossRef](#)] [[PubMed](#)]
83. Almeida, S.O.; Budoff, M. Effect of statins on atherosclerotic plaque. *Trends Cardiovasc. Med.* **2019**, *29*, 451–455. [[CrossRef](#)] [[PubMed](#)]
84. Oesterle, A.; Laufs, U.; Liao, J.K. Pleiotropic Effects of Statins on the Cardiovascular System. *Circ. Res.* **2017**, *120*, 229–243; Erratum in *Circ Res.* **2018**, *123*, e20. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

85. Stancu, C.; Sima, A. Statins: Mechanism of action and effects. *J. Cell Mol. Med.* **2001**, *5*, 378–387. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
86. Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; de Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E.; et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* **2019**, *139*, e1082–e1143, Erratum in *Circulation* **2023**, *148*, e5. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
87. Laffin, L.J.; Bruemmer, D.; Garcia, M.; Brennan, D.M.; McErlean, E.; Jacoby, D.S.; Michos, E.D.; Ridker, P.M.; Wang, T.Y.; Watson, K.E.; et al. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. *J. Am. Coll. Cardiol.* **2023**, *81*, 1–12. [[CrossRef](#)] [[PubMed](#)]
88. Silverman, M.G.; Ference, B.A.; Im, K.; Wiviott, S.D.; Giugliano, R.P.; Grundy, S.M.; Braunwald, E.; Sabatine, M.S. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. *JAMA* **2016**, *316*, 1289–1297. [[CrossRef](#)] [[PubMed](#)]
89. Timmis, A.; Vardas, P.; Townsend, N.; Torbica, A.; Katus, H.; De Smedt, D.; Gale, C.P.; Maggioni, A.P.; Petersen, S.E.; Huculeci, R.; et al. Atlas Writing Group, European Society of Cardiology. European Society of Cardiology: Cardiovascular disease statistics 2021. *Eur. Heart J.* **2022**, *43*, 716–799, Erratum in *Eur. Heart J.* **2022**, *43*, 799. [[CrossRef](#)] [[PubMed](#)]
90. Ward, N.C.; Watts, G.F.; Eckel, R.H. Statin Toxicity. *Circ. Res.* **2019**, *124*, 328–350. [[CrossRef](#)] [[PubMed](#)]
91. Chilbert, M.R.; VanDuyn, D.; Salah, S.; Clark, C.M.; Ma, Q. Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights. *Drug Des. Devel Ther.* **2022**, *16*, 2177–2186. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
92. Lamb, Y.N. Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. *Am. J. Cardiovasc. Drugs* **2020**, *20*, 381–392. [[CrossRef](#)] [[PubMed](#)]
93. Ferreira, A.M.; Marques da Silva, P. Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. *Am. J. Cardiovasc. Drugs* **2017**, *17*, 169–181. [[CrossRef](#)] [[PubMed](#)]
94. Murphy, S.A.; Cannon, C.P.; Blazing, M.A.; Giugliano, R.P.; White, J.A.; Lokhnygina, Y.; Reist, C.; Im, K.; Bohula, E.A.; Isaza, D.; et al. Reduction in Total Cardiovascular Events with Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. *J. Am. Coll. Cardiol.* **2016**, *67*, 353–361. [[CrossRef](#)] [[PubMed](#)]
95. Shaya, F.T.; Sing, K.; Milam, R.; Husain, F.; Del Aguila, M.A.; Patel, M.Y. Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses. *Am. J. Cardiovasc. Drugs* **2020**, *20*, 239–248. [[CrossRef](#)] [[PubMed](#)]
96. Hummelgaard, S.; Vilstrup, J.P.; Gustafsen, C.; Glerup, S.; Weyer, K. Targeting PCSK9 to tackle cardiovascular disease. *Pharmacol. Ther.* **2023**, *249*, 108480. [[CrossRef](#)] [[PubMed](#)]
97. Steffens, D.; Bramlage, P.; Scheeff, C.; Kasner, M.; Hassanein, A.; Friebel, J.; Rauch-Kröhnert, U. PCSK9 inhibitors and cardiovascular outcomes. *Expert Opin. Biol. Ther.* **2020**, *20*, 35–47. [[CrossRef](#)] [[PubMed](#)]
98. Gallego-Colon, E.; Daum, A.; Yosefy, C. Statins and PCSK9 inhibitors: A new lipid-lowering therapy. *Eur. J. Pharmacol.* **2020**, *878*, 173114. [[CrossRef](#)] [[PubMed](#)]
99. Rosenson, R.S.; Hegele, R.A.; Fazio, S.; Cannon, C.P. The Evolving Future of PCSK9 Inhibitors. *J. Am. Coll. Cardiol.* **2018**, *72*, 314–329. [[CrossRef](#)] [[PubMed](#)]
100. Gaba, P.; O'Donoghue, M.L.; Park, J.G.; Wiviott, S.D.; Atar, D.; Kuder, J.F.; Im, K.; Murphy, S.A.; De Ferrari, G.M.; Gaciong, Z.A.; et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. *Circulation* **2023**, *147*, 1192–1203. [[CrossRef](#)] [[PubMed](#)]
101. Giugliano, R.P.; Pedersen, T.R.; Park, J.G.; De Ferrari, G.M.; Gaciong, Z.A.; Ceska, R.; Toth, K.; Gouni-Berthold, I.; Lopez-Miranda, J.; Schiele, F.; et al. FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. *Lancet* **2017**, *390*, 1962–1971. [[CrossRef](#)] [[PubMed](#)]
102. Schwartz, G.G.; Steg, P.G.; Szarek, M.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Edelberg, J.M.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; et al. Odyssey Outcomes Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N. Engl. J. Med.* **2018**, *379*, 2097–2107. [[CrossRef](#)] [[PubMed](#)]
103. Ray, K.K.; Colhoun, H.M.; Szarek, M.; Baccara-Dinet, M.; Bhatt, D.L.; Bittner, V.A.; Budaj, A.J.; Diaz, R.; Goodman, S.G.; Hanotin, C.; et al. Odyssey Outcomes Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: A prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol.* **2019**, *7*, 618–628, Erratum in *Lancet Diabetes Endocrinol.* **2019**, *7*, e20. [[CrossRef](#)] [[PubMed](#)]
104. Grześk, G.; Dorota, B.; Wołowicz, Ł.; Wołowicz, A.; Osiak, J.; Kozakiewicz, M.; Banach, J. Safety of PCSK9 inhibitors. *Biomed. Pharmacother.* **2022**, *156*, 113957. [[CrossRef](#)] [[PubMed](#)]
105. Azari, S.; Rezapour, A.; Omidi, N.; Alipour, V.; Behzadifar, M.; Safari, H.; Tajdini, M.; Bragazzi, N.L. Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: A systematic review. *Heart Fail Rev.* **2020**, *25*, 1077–1088. [[CrossRef](#)] [[PubMed](#)]
106. Grundy, S.M.; Feingold, K.R. *Guidelines for the Management of High Blood Cholesterol*; Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., Hofland, J., et al., Eds.; Endotext; MDText.com, Inc.: South Dartmouth, MA, USA, 2000. [[PubMed](#)]

107. Wichaiyo, S.; Supharattanasitthi, W. Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia. *Clin. Drug Investig.* **2021**, *41*, 843–851. [[CrossRef](#)] [[PubMed](#)]
108. Laufs, U.; Banach, M.; Mancini, G.B.J.; Gaudet, D.; Bloedon, L.T.; Sterling, L.R.; Kelly, S.; Stroes, E.S.G. Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin Intolerance. *J. Am. Heart Assoc.* **2019**, *8*, e011662. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
109. Pinkosky, S.L.; Newton, R.S.; Day, E.A.; Ford, R.J.; Lhotak, S.; Austin, R.C.; Birch, C.M.; Smith, B.K.; Filippov, S.; Groot, P.H.E.; et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. *Nat. Commun.* **2016**, *7*, 13457. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
110. Banach, M.; Duell, P.B.; Gotto, A.M., Jr.; Laufs, U.; Leiter, L.A.; Mancini, G.B.J.; Ray, K.K.; Flaim, J.; Ye, Z.; Catapano, A.L. Association of Bempedoic Acid Administration with Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients with Hypercholesterolemia. *JAMA Cardiol.* **2020**, *5*, 1124–1135. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
111. Ray, K.K.; Bays, H.E.; Catapano, A.L.; Lalwani, N.D.; Bloedon, L.T.; Sterling, L.R.; Robinson, P.L.; Ballantyne, C.M. Clear Harmony Trial. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. *N. Engl. J. Med.* **2019**, *380*, 1022–1032. [[CrossRef](#)] [[PubMed](#)]
112. Goldberg, A.C.; Leiter, L.A.; Stroes, E.S.G.; Baum, S.J.; Hanselman, J.C.; Bloedon, L.T.; Lalwani, N.D.; Patel, P.M.; Zhao, X.; Duell, P.B. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. *JAMA* **2019**, *322*, 1780–1788, Erratum in *JAMA* **2020**, *323*, 282. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
113. Chandramahanti, S.; Farzam, K. *Bempedoic Acid*; StatPearls Publishing: Treasure Island, FL, USA, 2024. [[PubMed](#)]
114. Lawrence, E.; Johns, T. Bempedoic Acid (Nexletol) for the Treatment of Hyperlipidemia and Familial Hypercholesterolemia. *Am. Fam. Physician* **2021**, *103*, 377. [[PubMed](#)]
115. Ruscica, M.; Sirtori, C.R.; Carugo, S.; Banach, M.; Corsini, A. Bempedoic Acid: For Whom and When. *Curr. Atheroscler. Rep.* **2022**, *24*, 791–801. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
116. Perera, K.; Kam, N.; Ademi, Z.; Liew, D.; Zomer, E. Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis. *J. Clin. Lipidol.* **2020**, *14*, 772–783. [[CrossRef](#)] [[PubMed](#)]
117. Zhang, Y.; Chen, H.; Hong, L.; Wang, H.; Li, B.; Zhang, M.; Li, J.; Yang, L.; Liu, F. Inclisiran: A new generation of lipid-lowering siRNA therapeutic. *Front. Pharmacol.* **2023**, *14*, 1260921. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
118. Dec, A.; Niemiec, A.; Wojciechowska, E.; Maligłowska, M.; Bułdak, Ł.; Bołdys, A.; Okopień, B. Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy. *Int. J. Mol. Sci.* **2023**, *24*, 6858. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
119. Raschi, E.; Casula, M.; Cicero, A.F.G.; Corsini, A.; Borghi, C.; Catapano, A. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events. *Pharmacol. Ther.* **2023**, *250*, 108507. [[CrossRef](#)] [[PubMed](#)]
120. Wright, R.S.; Ray, K.K.; Raal, F.J.; Kallend, D.G.; Jaros, M.; Koenig, W.; Leiter, L.A.; Landmesser, U.; Schwartz, G.G.; Friedman, A.; et al. ORION Phase III Investigators. Pooled Patient-Level Analysis of Inclisiran Trials in Patients with Familial Hypercholesterolemia or Atherosclerosis. *J. Am. Coll. Cardiol.* **2021**, *77*, 1182–1193. [[CrossRef](#)] [[PubMed](#)]
121. Ray, K.K.; Kallend, D.; Leiter, L.A.; Raal, F.J.; Koenig, W.; Jaros, M.J.; Schwartz, G.G.; Landmesser, U.; Garcia Conde, L.; Wright, R.S. ORION-11 Investigators. Effect of inclisiran on lipids in primary prevention: The ORION-11 trial. *Eur. Heart J.* **2022**, *43*, 5047–5057. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
122. Ray, K.K.; Wright, R.S.; Kallend, D.; Koenig, W.; Leiter, L.A.; Raal, F.J.; Bisch, J.A.; Richardson, T.; Jaros, M.; Wijngaard, P.L.J.; et al. ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. *N. Engl. J. Med.* **2020**, *382*, 1507–1519. [[CrossRef](#)] [[PubMed](#)]
123. FDA Approves Add-On Therapy to Lower Cholesterol among Certain High-Risk Adults. Available online: <https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults> (accessed on 26 March 2024).
124. Leqvio—Inclisiran. Available online: <https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio> (accessed on 26 March 2024).
125. Katsiki, N.; Vrablik, M.; Banach, M.; Gouni-Berthold, I. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). *Pharmaceuticals* **2023**, *16*, 577. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
126. Albosta, M.S.; Grant, J.K.; Taub, P.; Blumenthal, R.S.; Martin, S.S.; Michos, E.D. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease. *Vasc. Health Risk Manag.* **2023**, *19*, 421–431. [[CrossRef](#)] [[PubMed](#)]
127. Ortega-Paz, L.; Capodanno, D.; Angiolillo, D.J. Canakinumab for secondary prevention of coronary artery disease. *Future Cardiol.* **2021**, *17*, 427–442. [[CrossRef](#)] [[PubMed](#)]
128. Attiq, A.; Afzal, S.; Ahmad, W.; Kandeel, M. Hegemony of inflammation in atherosclerosis and coronary artery disease. *Eur. J. Pharmacol.* **2024**, *966*, 176338. [[CrossRef](#)] [[PubMed](#)]
129. Roman, Y.M.; Hernandez, A.V.; White, C.M. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. *Ann. Pharmacother.* **2020**, *54*, 1021–1029. [[CrossRef](#)] [[PubMed](#)]
130. Viana-Huete, V.; Fuster, J.J. Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease. *Rev. Esp. Cardiol.* **2019**, *72*, 760. [[CrossRef](#)] [[PubMed](#)]
131. Russell, K.S.; Yates, D.P.; Kramer, C.M.; Feller, A.; Mahling, P.; Colin, L.; Clough, T.; Wang, T.; LaPerna, L.; Patel, A.; et al. A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease. *Vasc. Med.* **2019**, *24*, 414–421. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

132. Nguyen, M.T.; Fernando, S.; Schwarz, N.; Tan, J.T.; Bursill, C.A.; Psaltis, P.J. Inflammation as a Therapeutic Target in *Atherosclerosis*. *J. Clin. Med.* **2019**, *8*, 1109. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
133. Noels, H.; Weber, C.; Koenen, R.R. Chemokines as Therapeutic Targets in Cardiovascular Disease. *Arter. Thromb. Vasc. Biol.* **2019**, *39*, 583–592. [[CrossRef](#)] [[PubMed](#)]
134. Liberale, L.; Montecucco, F.; Schwarz, L.; Lüscher, T.F.; Camici, G.G. Inflammation and cardiovascular diseases: Lessons from seminal clinical trials. *Cardiovasc. Res.* **2021**, *117*, 411–422. [[CrossRef](#)] [[PubMed](#)]
135. Montarello, N.J.; Nguyen, M.T.; Wong, D.T.L.; Nicholls, S.J.; Psaltis, P.J. Inflammation in Coronary *Atherosclerosis* and Its Therapeutic Implications. *Cardiovasc. Drugs Ther.* **2022**, *36*, 347–362. [[CrossRef](#)] [[PubMed](#)]
136. Ma, J.; Chen, X. Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes. *Front. Cardiovasc. Med.* **2021**, *7*, 631398. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
137. Antonio, A.A.; Santos, R.N.; Abariga, S.A. Tocilizumab for giant cell arteritis. *Cochrane Database Syst. Rev.* **2022**, *5*, CD013484. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
138. Sano, M. Complexity of Inflammation in the Trajectory of Vascular Disease: Interleukin 6 and Beyond. *Ann. Vasc. Dis.* **2023**, *16*, 8–16. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
139. Castañeda, S.; Martínez-Quintanilla, D.; Martín-Varillas, J.L.; García-Castañeda, N.; Atienza-Mateo, B.; González-Gay, M.A. Tocilizumab for the treatment of adult-onset Still's disease. *Expert Opin. Biol. Ther.* **2019**, *19*, 273–286. [[CrossRef](#)] [[PubMed](#)]
140. Pierini, F.S.; Botta, E.; Soriano, E.R.; Martin, M.; Boero, L.; Meroño, T.; Saez, M.S.; Lozano Chiappe, E.; Cerda, O.; Citera, G.; et al. Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study. *Rheumatol. Ther.* **2021**, *8*, 803–815. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
141. Abubakar, M.; Rasool, H.F.; Javed, I.; Raza, S.; Abang, L.; Hashim, M.M.A.; Saleem, Z.; Abdullah, R.M.; Faraz, M.A.; Hassan, K.M.; et al. Comparative Roles of IL-1, IL-6, IL-10, IL-17, IL-18, IL-22, IL-33, and IL-37 in Various Cardiovascular Diseases with Potential Insights for Targeted Immunotherapy. *Cureus* **2023**, *15*, e42494. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
142. Ridker, P.M.; Rane, M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. *Circ. Res.* **2021**, *128*, 1728–1746. [[CrossRef](#)] [[PubMed](#)]
143. Fragoulis, G.E.; Soulaïdopoulos, S.; Sfikakis, P.P.; Dimitroulas, T.; DKitas, G. Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction. *J. Inflamm. Res.* **2021**, *14*, 1915–1931. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
144. Wang, Y.C.; Cui, X.B.; Chuang, Y.H.; Chen, S.Y. Janus Kinase 3, a Novel Regulator for Smooth Muscle Proliferation and Vascular Remodeling. *Arterioscler. Thromb. Vasc. Biol.* **2017**, *37*, 1352–1360. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
145. Shalabi, M.M.K.; Garcia, B.; Coleman, K.; Siller, A., Jr.; Miller, A.C.; Tying, S.K. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications. *Skin Ther. Lett.* **2022**, *27*, 4–9. [[PubMed](#)]
146. Benucci, M.; Bernardini, P.; Coccia, C.; De Luca, R.; Levani, J.; Economou, A.; Damiani, A.; Russo, E.; Amedei, A.; Guiducci, S.; et al. JAK inhibitors and autoimmune rheumatic diseases. *Autoimmun. Rev.* **2023**, *22*, 103276. [[CrossRef](#)] [[PubMed](#)]
147. Kirabo, A.; Oh, S.P.; Kasahara, H.; Wagner, K.U.; Sayeski, P.P. Vascular smooth muscle Jak2 deletion prevents angiotensin II-mediated neointima formation following injury in mice. *J. Mol. Cell Cardiol.* **2011**, *50*, 1026–1034. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
148. Shuai, K.; Liu, B. Regulation of JAK-STAT signalling in the immune system. *Nat. Rev. Immunol.* **2003**, *3*, 900–911. [[CrossRef](#)] [[PubMed](#)]
149. Welt, F.G.; Rogers, C. Inflammation and restenosis in the stent era. *Arterioscler. Thromb. Vasc. Biol.* **2002**, *22*, 1769–1776. [[CrossRef](#)]
150. Mangan, J.K.; Rane, S.G.; Kang, A.D.; Amanullah, A.; Wong, B.C.; Reddy, E.P. Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. *Blood* **2004**, *103*, 4093–4101. [[CrossRef](#)] [[PubMed](#)]
151. Abdul-Ghani, M.A.; Norton, L.; Defronzo, R.A. Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes. *Endocr. Rev.* **2011**, *32*, 515–531. [[CrossRef](#)]
152. Liu, Z.; Ma, X.; Ilyas, I.; Zheng, X.; Luo, S.; Little, P.J.; Kamato, D.; Sahebkar, A.; Wu, W.; Weng, J.; et al. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: From pharmacology to pre-clinical and clinical therapeutics. *Theranostics* **2021**, *11*, 4502–4515. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
153. Cai, X.; Yang, W.; Gao, X.; Chen, Y.; Zhou, L.; Zhang, S.; Han, X.; Ji, L. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. *Obesity* **2018**, *26*, 70–80. [[CrossRef](#)] [[PubMed](#)]
154. Rajeev, S.P.; Cuthbertson, D.J.; Wilding, J.P. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. *Diabetes Obes. Metab.* **2016**, *18*, 125–134. [[CrossRef](#)] [[PubMed](#)]
155. Davies, M.J.; Trujillo, A.; Vijapurkar, U.; Damaraju, C.V.; Meininger, G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. *Diabetes Obes. Metab.* **2015**, *17*, 426–429, Erratum in *Diabetes Obes. Metab.* **2015**, *17*, 708. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
156. Prattichizzo, F.; De Nigris, V.; Micheloni, S.; La Sala, L.; Ceriello, A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component? *Diabetes Obes. Metab.* **2018**, *20*, 2515–2522. [[CrossRef](#)] [[PubMed](#)]
157. Liao, X.; Sluimer, J.C.; Wang, Y.; Subramanian, M.; Brown, K.; Pattison, J.S.; Robbins, J.; Martinez, J.; Tabas, I. Macrophage autophagy plays a protective role in advanced atherosclerosis. *Cell Metab.* **2012**, *15*, 545–553. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

158. Chen, H.; Teng, D.; Xu, B.; Wang, C.; Wang, H.; Jia, W.; Gong, L.; Dong, H.; Zhong, L.; Yang, J. The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy. *J. Cardiovasc. Transl. Res.* **2023**, *16*, 999–1009. [[CrossRef](#)] [[PubMed](#)]
159. Nguyen Dinh Cat, A.; Montezano, A.C.; Burger, D.; Touyz, R.M. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. *Antioxid. Redox. Signal.* **2013**, *19*, 1110–1120. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
160. Honjo, T.; Yamaoka-Tojo, M.; Inoue, N. Pleiotropic effects of ARB in vascular metabolism--focusing on atherosclerosis-based cardiovascular disease. *Curr. Vasc. Pharmacol.* **2011**, *9*, 145–152. [[CrossRef](#)] [[PubMed](#)]
161. Marx, N.; Husain, M.; Lehrke, M.; Verma, S.; Sattar, N. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes. *Circulation* **2022**, *146*, 1882–1894. [[CrossRef](#)] [[PubMed](#)]
162. Arakawa, M.; Mita, T.; Azuma, K.; Ebato, C.; Goto, H.; Nomiyama, T.; Fujitani, Y.; Hirose, T.; Kawamori, R.; Watada, H. Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin. *Diabetes* **2010**, *59*, 1030–1037. [[CrossRef](#)]
163. Vinué, Á.; Navarro, J.; Herrero-Cervera, A.; García-Cubas, M.; Andrés-Blasco, I.; Martínez-Hervás, S.; Real, J.T.; Ascaso, J.F.; González-Navarro, H. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. *Diabetologia* **2017**, *60*, 1801–1812. [[CrossRef](#)]
164. Anholm, C.; Kumarathurai, P.; Pedersen, L.R.; Samkani, A.; Walzem, R.L.; Nielsen, O.W.; Kristiansen, O.P.; Fenger, M.; Madsbad, S.; Sajadieh, A.; et al. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. *Atherosclerosis* **2019**, *288*, 60–66. [[CrossRef](#)] [[PubMed](#)]
165. Hogan, A.E.; Gaoatswe, G.; Lynch, L.; Corrigan, M.A.; Woods, C.; O'connell, J.; O'shea, D. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. *Diabetologia* **2014**, *57*, 781–784. [[CrossRef](#)]
166. Wu, M.D.; Atkinson, T.M.; Lindner, J.R. Platelets and von Willebrand factor in atherogenesis. *Blood* **2017**, *129*, 1415–1419. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
167. Undas, A.; Brummel-Ziedins, K.E.; Mann, K.G. Antithrombotic properties of aspirin and resistance to aspirin: Beyond strictly antiplatelet actions. *Blood* **2007**, *109*, 2285–2292. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
168. de Gaetano, G.; Cerletti, C.; Dejana, E.; Latini, R. Pharmacology of platelet inhibition in humans: Implications of the salicylate-aspirin interaction. *Circulation* **1985**, *72*, 1185–1193. [[CrossRef](#)] [[PubMed](#)]
169. Kharbanda, R.K.; Walton, B.; Allen, M.; Klein, N.; Hingorani, A.D.; MacAllister, R.J.; Vallance, P. Prevention of inflammation-induced endothelial dysfunction: A novel vasculo-protective action of aspirin. *Circulation* **2002**, *105*, 2600–2604. [[CrossRef](#)] [[PubMed](#)]
170. López-Farré, A.J.; Modrego, J.; Azcona, L.; Guerra, R.; Segura, A.; Rodríguez, P.; Zamorano-León, J.J.; Lahera, V.; Macaya, C. Nitric oxide from mononuclear Cells may be involved in platelet responsiveness to aspirin. *Eur. J. Clin. Investig.* **2014**, *44*, 463–469. [[CrossRef](#)] [[PubMed](#)]
171. Xue, Y.; Wang, Z.; Wu, H.; Li, X.; Chen, J.; Lv, Q. Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome. *J. Clin. Pharm. Ther.* **2021**, *46*, 328–332. [[CrossRef](#)] [[PubMed](#)]
172. Sohn, M.; Lim, S. The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis. *Int. J. Mol. Sci.* **2024**, *25*, 2593. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
173. Manickavasagam, S.; Ye, Y.; Lin, Y.; Perez-Polo, R.J.; Huang, M.H.; Lui, C.Y.; Hughes, M.G.; McAdoo, D.J.; Uretsky, B.F.; Birnbaum, Y. The cardioprotective effect of a statin and cilostazol combination: Relationship to Akt and endothelial nitric oxide synthase activation. *Cardiovasc. Drugs Ther.* **2007**, *21*, 321–330. [[CrossRef](#)] [[PubMed](#)]
174. Li, H.; Hong, D.H.; Son, Y.K.; Na, S.H.; Jung, W.K.; Bae, Y.M.; Seo, E.Y.; Kim, S.J.; Choi, I.W.; Park, W.S. Cilostazol induces vasodilation through the activation of Ca<sup>2+</sup>-activated K<sup>(+)</sup> channels in aortic smooth muscle. *Vascul. Pharmacol.* **2015**, *70*, 15–22. [[CrossRef](#)] [[PubMed](#)]
175. Tani, T.; Uehara, K.; Sudo, T.; Marukawa, K.; Yasuda, Y.; Kimura, Y. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. *Atherosclerosis* **2000**, *152*, 299–305. [[CrossRef](#)] [[PubMed](#)]
176. Hirose, T.; Kurebayashi, S.; Kasayama, S. Antiplatelet agent cilostazol potentiates adipocyte differentiation of 3T3-L1 cells. *Atherosclerosis* **2001**, *158*, 19–22. [[CrossRef](#)] [[PubMed](#)]
177. Kim, H.J.; Moon, J.H.; Kim, H.M.; Yun, M.R.; Jeon, B.H.; Lee, B.; Kang, E.S.; Lee, H.C.; Cha, B.S. The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression. *Metabolism* **2014**, *63*, 112–119. [[CrossRef](#)] [[PubMed](#)]
178. Everett, B.M.; Donath, M.Y.; Pradhan, A.D.; Thuren, T.; Pais, P.; Nicolau, J.C.; Glynn, R.J.; Libby, P.; Ridker, P.M. Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes. *J. Am. Coll. Cardiol.* **2018**, *71*, 2392–2401. [[CrossRef](#)] [[PubMed](#)]
179. Mora, S.; Glynn, R.J.; Hsia, J.; MacFadyen, J.G.; Genest, J.; Ridker, P.M. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: Results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. *Circulation* **2010**, *121*, 1069–1077. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

180. Kautzky-Willer, A.; Harreiter, J.; Pacini, G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr. Rev.* **2016**, *37*, 278–316. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
181. Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.; Raal, F.J.; Schunkert, H.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur. Heart J.* **2017**, *38*, 2459–2472. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
182. Kallend, D.; Stoekenbroek, R.; He, Y.; Smith, P.F.; Wijngaard, P. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. *J. Clin. Lipidol.* **2022**, *16*, 208–219. [[CrossRef](#)] [[PubMed](#)]
183. Arnott, C.; Li, Q.; Kang, A.; Neuen, B.L.; Bompoint, S.; Lam, C.S.P.; Rodgers, A.; Mahaffey, K.W.; Cannon, C.P.; Perkovic, V.; et al. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *J. Am. Heart Assoc.* **2020**, *9*, e014908. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
184. McSweeney, J.C.; Rosenfeld, A.G.; Abel, W.M.; Braun, L.T.; Burke, L.E.; Daugherty, S.L.; Fletcher, G.F.; Gulati, M.; Mehta, L.S.; Pettey, C.; et al. American Heart Association Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Hypertension, Council on Lifestyle and Cardiometabolic Health, and Council on Quality of Care and Outcomes Research. Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science: A Scientific Statement from the American Heart Association. *Circulation* **2016**, *133*, 1302–1331. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
185. Messner, B.; Bernhard, D. Smoking and cardiovascular disease: Mechanisms of endothelial dysfunction and early atherogenesis. *Arterioscler. Thromb. Vasc. Biol.* **2014**, *34*, 509–515. [[CrossRef](#)] [[PubMed](#)]
186. Heishman, S.J.; Kleykamp, B.A.; Singleton, E.G. Meta-analysis of the acute effects of nicotine and smoking on human performance. *Psychopharmacology* **2010**, *210*, 453–469. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
187. McLaughlin, I.; Dani, J.A.; De Biasi, M. Nicotine withdrawal. *Curr. Top Behav. Neurosci.* **2015**, *24*, 99–123. [[CrossRef](#)] [[PubMed](#)]
188. Gotti, C.; Clementi, F. Cytisine and cytosine derivatives. More than smoking cessation aids. *Pharmacol. Res.* **2021**, *170*, 105700. [[CrossRef](#)] [[PubMed](#)]
189. Crawford, P.; Cieslak, D. Varenicline for Smoking Cessation. *Am. Fam. Physician.* **2017**, *96*. [[PubMed](#)]
190. Howes, S.; Hartmann-Boyce, J.; Livingstone-Banks, J.; Hong, B.; Lindson, N. Antidepressants for smoking cessation. *Cochrane Database Syst. Rev.* **2020**, *4*, CD000031, Update in: *Cochrane Database Syst. Rev.* **2023**, *5*, CD000031. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
191. Matei, D.; Buculei, I.; Luca, C.; Corciova, C.P.; Andritoi, D.; Fuior, R.; Iordan, D.A.; Onu, I. Impact of Non-Pharmacological Interventions on the Mechanisms of Atherosclerosis. *Int. J. Mol. Sci.* **2022**, *23*, 9097. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
192. Riccardi, G.; Giosuè, A.; Calabrese, I.; Vaccaro, O. Dietary recommendations for prevention of atherosclerosis. *Cardiovasc. Res.* **2022**, *118*, 1188–1204. [[CrossRef](#)] [[PubMed](#)]
193. Ahrens, A.P.; Culpepper, T.; Saldivar, B.; Anton, S.; Stoll, S.; Handberg, E.M.; Xu, K.; Pepine, C.; Triplett, E.W.; Aggarwal, M. A Six-Day, Lifestyle-Based Immersion Program Mitigates Cardiovascular Risk Factors and Induces Shifts in Gut Microbiota, Specifically Lachnospiraceae, Ruminococcaceae, Faecalibacterium prausnitzii: A Pilot Study. *Nutrients* **2021**, *13*, 3459. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
194. Jeong, S.Y.; Wee, C.C.; Kovell, L.C.; Plante, T.B.; Miller, E.R., 3rd; Appel, L.J.; Mukamal, K.J.; Juraschek, S.P. Effects of Diet on 10-Year Atherosclerotic Cardiovascular Disease Risk (from the DASH Trial). *Am. J. Cardiol.* **2023**, *187*, 10–17, Erratum in *Am. J. Cardiol.* **2024**, *216*, 112–113. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
195. Visioli, F.; Poli, A. Prevention and Treatment of Atherosclerosis: The Use of Nutraceuticals and Functional Foods. *Handb. Exp. Pharmacol.* **2022**, *270*, 271–285. [[CrossRef](#)] [[PubMed](#)]
196. Maki, K.C.; Dicklin, M.R. Is there an optimal diet for primordial prevention of atherosclerosis? *Eur. Heart J.* **2022**, *43*, 3189–3191. [[CrossRef](#)] [[PubMed](#)]
197. Wei, T.; Liu, J.; Zhang, D.; Wang, X.; Li, G.; Ma, R.; Chen, G.; Lin, X.; Guo, X. The Relationship Between Nutrition and Atherosclerosis. *Front. Bioeng. Biotechnol.* **2021**, *9*, 635504. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.